SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
X Annual report pursuant to Section 13 or 15 (d) of the Securities
Exchange Act of 1934 (Fee required)
For the fiscal year ended August 31, 1995 or
Transition report pursuant to Section 13 or 15 (d) of the Securities
Exchange Act 1934 (No fee required)
For the transition period from to
Commission file number: 0-17005
DEKALB Genetics Corporation
(Exact name of registrant as specified in its charter)
Delaware 36-3586793
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
3100 Sycamore Road, DeKalb, Illinois 60115
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 815-758-3461
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Title of Class
Class A Common Stock, no par value
Class B Common Stock, no par value
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K. __
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d)of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes X No
As of September 30, 1995, 769,881 shares of the registrant's Class A Common
Stock and 4,416,655 shares of the registrants' Class B Common Stock were
outstanding and the aggregate market value of all Common Stock held by
non-affiliates was $215,720,835 based upon the closing price on the NASDAQ
National Market System on such date. (The officers and directors of the
registrant are considered affiliates for purposes of this calculation.)
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Proxy Statement pertaining to the annual shareholders' meeting
are incorporated herein by reference into Part III.
Exhibit index is located on page 43.
Total number of pages is 61.
<PAGE>
PART I
ITEM 1. BUSINESS
(a) DEKALB Genetics Corporation ("Genetics" or the "Company") is
engaged in the development of products of major importance to two segments
of modern agriculture--seed (primarily corn, soybeans, sorghum, alfalfa and
sunflower) and hybrid swine breeding stock. Genetics operates two business
segments, one through the seed division of the Company ("DEKALB Seed") and
one through its wholly-owned subsidiary, DEKALB Swine Breeders, Inc.
("DEKALB Swine").
Genetics conducts major research and development programs on those
genetically determined traits which are of primary importance to the
profitability of a farmer's production. The Company develops primary or
inbred lines through a process of observation, evaluation and selection
for further breeding only of those plants or swine which exhibit superior
performance in certain traits. These primary or inbred lines, when mated
or crossed to other primary or inbred lines, will pass on to their progeny
the superior performance in those traits for which the primary or inbred
lines were selected. Additionally, a fundamental genetic
principle--called heterosis, or hybrid vigor--is generally utilized.
Heterosis occurs when the progeny of genetically dissimilar parents have
certain performance characteristics which are superior to those of either
parent.
Genetics uses these principles of genetic selection and heterosis to
provide products for the modern day agricultural industry. The Company
also develops production and management techniques to complement the
performance potential which resides in the genetic composition of its
products.
Genetics is a Delaware corporation which was organized on June 15, 1988.
It succeeded to the genetics businesses of DEKALB Corporation which was
originally founded in 1917.
(b) Industry and Geographic Segment Information is included in Part II,
Item 8, Footnotes R and N of the financial statements.
(c) The following narrative describes the businesses of each segment and other
general matters of the Company.
SEED
DEKALB Seed, headquartered in DeKalb, Illinois, engages in the research and
development of hybrid corn, varietal soybean, hybrid sorghum, hybrid
sorghum-sudangrass and hybrid sunflower seed. The Company contracts with
growers to produce the seeds of such plants, and markets them under the DEKALB
brand. It also markets varietal alfalfa and other forage mixtures.
Research and Development
Crop producers are very conscious of product performance and respond to new,
improved products. As a research-based company, Genetics commits significant
resources (approximately 13 percent of DEKALB Seed consolidated worldwide
revenues) to the research and development of improved products. Total
worldwide research and development expenditures by DEKALB Seed were $35.4
million, $33.6 million and $34.7 million for fiscal years 1995, 1994, and
1993, respectively.
<PAGE>
DEKALB Seed operates an integrated, worldwide research and development effort,
conducted at 55 research locations and 536 testing sites around the world,
with 35 research locations and 311 test sites in the United States and Canada.
Worldwide, it has 35 corn breeding programs, seven sorghum breeding programs,
three soybean breeding programs, and three sunflower breeding programs.
Throughout the world new hybrids and varieties are evaluated annually, and in
the United States and Canada there are over 983,000 performance test plots.
DEKALB Seed has a biotechnology research facility in Mystic, Connecticut,
which includes a laboratory, greenhouse and general office and represents
approximately 15 percent of total R&D spending.
Products
In 1995, sales of hybrid corn seed represented approximately 66
percent of DEKALB Seed consolidated worldwide revenues. Corn is the primary
feed grain grown in the United States and worldwide and has a seed market
value of approximately $1.7 billion in the United States and $4.5 billion
worldwide, the largest of any agricultural seed. Corn is planted under a wide
variety of conditions which affect its growth and yield, including the length
of the growing season (which is primarily determined by latitude and
altitude), water availability, soil, climate and insect and disease
challenges. To respond to this variety of conditions, DEKALB Seed has
developed high yielding corn plants with different relative characteristics in
terms of maturity (time from planting to harvest), dry down (time it takes for
the corn to dry to harvest standards), grain quality, standability (strength
of roots and stalks), insect and disease resistance, plant and ear height and
tolerance to drought and other stresses.
Soybean acreage in the United States is third behind corn and wheat acreage,
and in fiscal year 1995, the sale of soybean seed represented approximately 18
percent of DEKALB Seed consolidated worldwide total revenues. DEKALB Seed has
developed high-yielding soybean varieties with characteristics differing on
the basis of maturity, tolerance to disease, seedling emergence, standability
of the plant, and resistance to shattering (the premature opening of the bean
pod).
DEKALB Seed produces both grain and forage types of hybrid sorghum seed. In
fiscal year 1995, sales of hybrid sorghum seed represented approximately six
percent of DEKALB Seed consolidated worldwide revenues. The grain sorghum
product line is planted by farmers to produce a high-quality feed grain,
approaching the value of corn. The DEKALB research effort continues to focus
on developing hybrids which possess consistently high yields, resistance to
lodging and greenbug attacks and drought tolerance, since more than 80 percent
of the crop is grown under semi-arid rainfall conditions.
DEKALB Seed is able to serve the requirements of several sunflower seed
markets through development of a range of hybrids. These hybrids exhibit high
yield, high oil content, a range of maturities, standability and disease
resistance. Currently, sunflower seeds are marketed primarily in Argentina,
France, and Italy. Sunflower seed sales represented four percent of DEKALB
Seed consolidated worldwide revenues in 1995.
Virtually all corn and sorghum seed planted in the United States and
practically all sunflower seed planted world-wide are hybrids. Because the
seeds (grain) produced by a hybrid do not have the same genetic composition as
the seed planted, farmers purchase nearly all of their corn and sorghum seed
each year so as not to lose the full benefits of genetic selection and
heterosis. That is, if they hold back corn, sorghum or most sunflower seed
from their crop and plant it the next year, yield and other positive
attributes will be dramatically reduced.
<PAGE>
Soybeans, on the other hand, are not hybrids. Farmers frequently retain and
use a part of their crop as seed in the year following harvest. Thus, there
is a reduced market as well as lower profit margin potential for commercial
soybean seed. An April, 1995 change in the Plant Variety Protection Act, a
law governing the use of proprietary soybean varieties, limits the quantity of
seed a grower may retain and should improve prospects for capturing the
benefits of soybean research investment.
DEKALB Seed also produces and sells SUDAX (registered trademark) brand
sorghum-sudangrass and sells alfalfa. SUDAX (registered trademark) brand is
a hybrid cross of sorghum and sudangrass, producing
a plant suitable for pasturing animals or multiple cuttings for forage or hay.
Alfalfa is used as animal feed, primarily for dairy and feeder cattle.
Alfalfa is a perennial, as it will re-emerge for many seasons without
additional seeding.
Production of hybrid seed involves various environmental risks. The parental
inbred lines which are used in production are more sensitive to adverse
conditions than are commercial hybrids grown by farmers. Weather is the
biggest variable. Wet weather at planting time, lack of moisture during the
growing season, hot weather at pollination time and frost before the crop is
mature can all adversely affect DEKALB Seed's supply and unit costs. For
these reasons, DEKALB Seed has its production facilities spread geographically
and frequently utilizes irrigation to minimize some of these risks.
Marketing
In the United States, DEKALB Seed markets seed from coast to
coast, through a large network of about 7,000 independent farmer-dealers,
distributors and farm stores who resell to approximately 117,000 farmers.
There are approximately 300 companies engaged in the production and marketing
of agricultural seed, resulting in intense competition. DEKALB Seed estimates
that the top two -- Pioneer Hi-Bred International, Inc. of Des Moines, Iowa
and DEKALB Seed -- accounted for approximately 55 percent of 1995 United
States seed corn sales, and that the next six companies have a combined market
share of nearly 18 percent. DEKALB Seed is the second largest seller of corn
seed with a market share of approximately 10 percent and is one of the largest
sellers of soybean and sorghum seed in the United States. Competition for
sales of seed to farmers involves factors such as relative product
performance, price, marketing and promotional programs, technical support,
customer relationships and the effectiveness of the sales force. DEKALB
management believes it competes favorably with respect to all these factors.
International Operations
The international seed business has similar risks and competition as the
United States seed business, plus the added risks of different political
environments and currency fluctuations. From its initial
activities in 1959, the international seed business unit of DEKALB Seed has
expanded to most areas of the world where corn, sorghum, soybean, alfalfa and
sunflower are grown.
DEKALB Seed, directly or indirectly, operates wholly-owned subsidiaries in
Argentina, Italy, Honduras and Austria and has a 51% owned subsidiary in
Columbia and a 49% owned affiliate in Mexico. During fiscal 1993, DEKALB
ceased its company-owned operations in Australia and Spain and currently does
business in Australia through a licensee and in Spain through a distributor.
In addition, foreign-based companies in major agricultural markets have been
licensed to produce and market DEKALB seed. Thus, local production and
marketing is carried out in more than 20 countries worldwide. The agreements
with these foreign affiliates provide for the development, production and sale
<PAGE>
of hybrids and varieties adapted to meet local market preferences.
International revenues through consolidated subsidiaries totaled over $72
million in 1995. In addition, it is estimated that DEKALB brand seed sales
through non-consolidated foreign affiliates and licensees totaled
approximately $130 million.
Seasonality
Production, sale and distribution of seed follows a seasonal
pattern. In North America, DEKALB Seed normally grows its seed supply in the
summer, and it is harvested, conditioned, and bagged in the months of
September through January. The dealers' sales effort takes place in the fall,
and generally about three-fourths of farmers' seed orders are placed by
December 1st. Deliveries of seed corn occur principally in the late winter
and spring, during the Company's second and third fiscal quarters. Sales
revenue is recognized upon shipment of seed. Returns of unsold seed occur, in
most cases, during the fourth fiscal quarter. At the time sales are recorded,
DEKALB Seed provides for estimated returns based upon historical experience
and current weather conditions. During the past three years, approximately 60
percent and 40 percent of North American seed revenues were recorded in the
second and third fiscal quarters, respectively. Cash collections also follow
a seasonal pattern, as the majority of dealers remit cash in advance of their
first due date in June in order to earn discounts for early payment.
Approximately two-thirds of DEKALB Seed's cash outflow in North America occurs
in the months of December through April and includes payments to independent
farmers who have contracted to produce DEKALB Seed products.
The demand for seed reflects the demand for the crop's end use including
animal feed, industrial use and food consumption. The cyclical nature of the
business creates uncertainty from year to year concerning the size of the
market for seed. An inaccurate estimate of seed needs can result in an
undersupply of seed products or an oversupply of seed (which may create the
need to write off inventories).
Patents and Applications
Patents, trademarks, United States Plant Variety
Protection Act Certificates, foreign plant registrations and licenses to use
genetic material and/or intellectual property are growing in importance,
generally, to the industry and to the business of DEKALB Seed. While no
single patent is currently of material importance to the Company's seed
business, an increasing number of patents that have been issued to the Company
in the area of biotechnology are considered to be a key success factor in
order to commercialize genetically engineered products in the future.
DEKALB Seed's policy is to fully protect its inventions, discoveries and
intellectual property. DEKALB Seed has obtained numerous U.S. patents, Plant
Variety Protection Act Certificates, and foreign registrations.
SWINE
DEKALB Swine, headquartered in DeKalb, Illinois, engages in the research and
development of hybrid swine breeding stock and markets such hybrid breeding
swine and related management services to hog producers in both domestic and
international markets.
Research and Development
Through genetic research and development, male and
female lines of swine have been developed which are unique to DEKALB Swine.
These DEKALB Swine lines undergo continual genetic improvement through
research which includes an ongoing process of observation, testing,
statistical analysis and selection for further breeding of only those swine
exhibiting superiority in economically important traits.
DEKALB Swine's research and development expenditures were $5.8 million, $6.4
million and $5.7 million for fiscal years 1995, 1994 and 1993, respectively.
<PAGE>
Products and Programs
Domestically, DEKALB Swine generates breeding stock
sales and license revenues from five principal programs (Specific Cross
(registered trademark) Program, hybrid boar rotation, Custom Genetics
(registered trademark) Program, crossing farms, and artificial insemination
centers) through which it markets hybrid breeding swine and semen.
Internationally, DEKALB Swine licenses or sells primary lines to third parties
for the production of breeding stock in the foreign country under trademark
licenses and technical agreements. DEKALB Swine also directly sells hybrid
boars and gilts to foreign customers.
DEKALB Swine's secondary product is market hogs, which are a by-product of the
production of breeding animals and represents about 40 percent of total
revenues. Because DEKALB Swine produces a consistent and high quality
product, this market hog by-product is generally sold by DEKALB Swine at a
premium above major slaughter market averages.
Marketing
In the United States, DEKALB Swine sells breeding stock to
approximately 1,600 customers who fall into two broad categories. First,
larger hog producers (producers who maintain over 200 sows) represent a major
market for DEKALB Swine's products. As the number of hog producers has
declined by 50 percent over the past ten years to approximately 209,000 hog
farms, these larger producers represent a growing share of hog production,
and an increasing percentage of DEKALB Swine's breeding stock sales. Larger
producers purchase boars or boar semen and either purchase gilts, or in many
cases, operate an in-house "crossing farm" and pay DEKALB Swine fees by
licensing DEKALB grandparent lines to produce their own gilts. Second, DEKALB
Swine's smaller customers (producers who maintain less than 200 sows)
primarily purchase DEKALB Swine boars and generally retain gilts from their
own herds.
Internationally, DEKALB Swine currently licenses or sells swine breeding stock
to distributors in seven foreign countries. Those distributors sell offspring
to several hundred local customers.
Competition
In the United States, DEKALB Swine competes with seven national
and several regional producers of hybrid swine breeding stock and thousands of
producers of purebred stock. DEKALB Swine believes that it is one of the
largest producers of hybrid breeding stock in the United States.
The demand for swine breeding stock depends upon the supply of hogs to be
produced, which is determined by the profitability of hog production, which,
in turn, depends upon the supply and demand for pork and pork products, as
well as the cost of production. The demand for DEKALB Swine breeding stock
depends upon customer acceptance and the ability to offer products and
services which are superior to the competition.
Breeding stock prices are influenced by the quality of the breeding stock, by
competition from other major hybrid producers and purebred producers and by
slaughter market prices. On average, hybrid breeding stock sells at a higher
price than purebred swine.
In addition to price, competition for sales to hog producers involves factors
such as reproductive performance of the parent hybrid boars and gilts,
performance and quality of their market hog offspring, technical knowledge and
competence of the sales force, service programs and post-sale support. DEKALB
Swine management believes it competes favorably with respect to all these
factors.
<PAGE>
The swine industry is a cyclical business that is heavily influenced by
producer profitability. Historically, hog production has followed a three to
five year expansion phase followed by a similar contraction phase. At the
peak of the expansion phase, market hog prices are generally at a low and
unprofitable level. As hog production decreases, prices normally begin to
rise until expansion again begins to occur.
GENERAL
On August 31, 1995, Genetics had approximately 1,800 employees.
Working capital requirements in the seed business arise out of the need to
carry newly produced inventories of seed (principally corn), and payables to
growers associated with growing that hybrid seed, until receipts from the
selling season are collected several months later. DEKALB Seed, therefore,
has significant working capital requirements from January 1 to July 1 of each
year because approximately two-thirds of DEKALB Seed's cash flow for expenses
occurs in the months of December through April, although final receipts are
not received until June. It is anticipated that such requirements will be met
through cash generated from operations and lines of credit for general
corporate purposes.
Genetics has available various credit facilities which include a revolving
line of credit. The revolving credit agreement provides for a $50 million
line of credit for general corporate purposes, and has a required step-down to
$20 million for one day during each year.
DEKALB Swine's production and sales patterns are such that working capital
needs are relatively stable.
The operations of Genetics are subject to various state and federal
environmental and safety laws, rules and regulations. Certain of the
facilities of Genetics are also subject to state and federal environmental
protection laws, rules and regulations. Management of Genetics believes that
the Company is in compliance, in all material respects, with applicable
environmental and safety laws, rules and regulations and that such compliance
has not had any material adverse effect on its operations or financial
condition.
ITEM 2. PROPERTIES
In both its seed and swine businesses, Genetics' property consists primarily
of foundation genetic material and the property, buildings and related
equipment for research, production, distribution and marketing.
DEKALB Seed headquarters personnel occupy a 73,000 square foot office building
and DEKALB Swine headquarters personnel occupy a 15,000 square foot office
building, both of which are located in DeKalb, Illinois and are owned by the
Company. DEKALB Seed also owns facilities in DeKalb, Illinois that are used
for seed research.
DEKALB Seed owns or leases 36 facilities in the United States and 21 outside
of the United States at which research functions are performed, 26 seed
production and foundation locations in the United States and seven outside the
United States, and two seed warehouses in the United States. DEKALB Seed owns
or leases 13 sales offices, all in the United States plus a biotechnology
research facility in Mystic, Connecticut.
<PAGE>
DEKALB Swine owns 18 research, foundation and production farms and 10 genetic
evaluation stations. Thirteen of the farms, as well as an office and modern
feed mill, are located in Seward and Meade Counties, Kansas and nearby Beaver
and Texas Counties, Oklahoma. Three farms are located near the corporate
headquarters in DeKalb, Illinois with two additional farms near Lubbock,
Texas.
Genetics believes its facilities are adequate to serve its needs and that if
additional facilities are required as the business expands, Genetics will be
able to acquire or lease such facilities on reasonable terms.
ITEM 3. LEGAL PROCEEDINGS
Management is of the opinion that pending legal proceedings will not result in
a material adverse effect on the consolidated operations or financial position
of the Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to the vote of security holders during the fourth
quarter of 1995.
<PAGE>
EXECUTIVE OFFICERS OF THE REGISTRANT
The names, ages, and positions of the executive officers of the Company,
with their business experience during the past five years, are shown below.
Corporate officers are elected annually by the Board of Directors.
Age
Bruce P. Bickner. . . . . . . . . . . . . . . . . . . . . . . 52
Chairman of the Board, Chief Executive Officer and Director of the Company
Mr. Bickner has served as Chairman of the Board, Chief Executive Officer and
Director of the Company during the past five years. He was Chairman of the
Board and Chief Executive Officer of DEKALB Energy Company until January,
1992, when he was elected to the additional position of President. He
relinquished the titles of President and Chief Executive Officer in November,
1992. He resigned from all positions with DEKALB Energy Company upon the sale
of the Company in May 1995.
Richard O. Ryan . . . . . . . . . . . . . . . . . . . . . . . 53
President, Chief Operating Officer and Director of the Company
Mr. Ryan has served as President, Chief Operating Officer and Director of the
Company during the past five years.
Richard T. Crowder. . . . . . . . . . . . . . . . . . . . . . 56
Senior Vice President, International of the Company
Mr. Crowder served as Under Secretary, U.S. Department of Agriculture until
July, 1992 at which time he was appointed Executive Vice President and General
Manager, Armour Swift Eckridge. He remained in that position until he was
elected Senior vice President of the Company in October 1994.
John H. Witmer, Jr. . . . . . . . . . . . . . . . . . . . . . 55
Senior Vice President, General Counsel and Secretary of the Company
Mr. Witmer has served as Senior Vice President, General Counsel and Secretary
of the Company during the past five years. He served as Senior Vice President
of DEKALB Energy Company until he relinquished the title of Senior Vice
President and was elected Vice President in November, 1992. He resigned from
all positions with DEKALB Energy Company upon the sale of the Company in May,
1995.
Thomas R. Rauman. . . . . . . . . . . . . . . . . . . . . . . 47
Vice President, Finance and Chief Financial Officer of the Company
Mr. Rauman was elected Vice President, Finance, Chief Financial Officer and
Treasurer of the Company in January, 1993. He relinquished the position of
Treasurer in July, 1993. He was Vice President and Controller of DEKALB
Energy Company until January, 1992, when he was elected Vice President,
Finance, Chief Financial Officer and Treasurer. He resigned from all
positions with DEKALB Energy Company in December, 1992.
Janis M. Felver . . . . . . . . . . . . . . . . . . . . . . . 48
Controller and Chief Accounting Officer of the Company
Ms. Felver served as Assistant Controller of the Company until January 1995 at
which time she was elected Controller and Chief Accounting Officer.
Roy L. Poage. . . . . . . . . . . . . . . . . . . . . . . . . 63
President, DEKALB Swine Breeders, Inc.
Mr. Poage has served as President of DEKALB Swine Breeders during the past
five years.
Each officer of DEKALB Genetics Corporation has been elected to serve as
such until the next annual election of officers of Genetics (expected to occur
on January 17, 1996) or until his successor is elected.
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
A. As of September 30, 1995 there were approximately 800 record holders
of Class A Common Stock and 1,900 record holders of Class B Common Stock.
Class B shares are currently being traded on the NASDAQ/NMS over-the-counter
market under the trading symbol SEEDB. There is no established public trading
market for Class A shares.
B. Common Stock Data 1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr.
1995
Dividends per share $.20 $.20 $.20 $.20
Market price range - Low $27.75 $24.50 $29.00 $38.50
- High $32.88 $29.75 $37.75 $44.75
1994
Dividends per share $.20 $.20 $.20 $.20
Market price range - Low $24.75 $28.50 $30.50 $27.50
- High $31.75 $35.00 $36.00 $33.50
<TABLE>
ITEM 6 - SELECTED FIVE-YEAR FINANCIAL DATA
<CAPTION>
Years Ended August 31 --
(Dollars in millions, except per share amounts)
1995 1994 1993 1992 1991
<S> <C> <C> <C> <C> <C>
OPERATIONS DATA
Revenues:
North American Seed $199.9 $183.8 $162.7 $176.8 $165.2
International Seed 72.1 63.7 69.6 64.6 48.8
Swine 47.4 52.7 45.1 44.5 47.0
Total Operating Revenues $319.4 $300.2 $277.4 $285.9 $261.0
Pre-Tax Earnings (Loss):
North American Seed $22.3 $14.7 $5.2 $10.1 $17.8
International Seed 7.6 8.0 3.3 9.9 7.0
Swine (0.9) 5.7 3.0 4.6 9.3
Interest, corporate and other (13.9) (13.2) (14.1) (10.7) (10.4)
Earnings before income taxes and
discontinued operations 15.1 15.2 (2.6) 13.9 23.7
Income tax provision (benefit) 5.6 4.6 (3.4) 4.4 8.3
Earnings before discontinued operations 9.5 10.6 0.8 9.5 15.4
Discontinued operations 1.2 - 0.9 0.8 1.7
Net earnings $10.7 $10.6 $1.7 $10.3 $17.1
PER SHARE DATA
Primary earnings per share (1) $2.04 $2.02 $0.33 $1.99 $3.09
Fully diluted earnings per share (2) - - - - $2.91
Dividends per share $0.80 $0.80 $0.80 $0.80 $0.80
FINANCIAL DATA
Return on average equity 8.6% 9.0% 1.5% 9.1% 15.1%
Current ratio 1.85 1.75 1.70 2.22 2.67
Working capital $80.4 $68.9 $67.7 $86.0 $78.9
Net property, plant and equipment $99.8 $95.7 $87.8 $83.5 $70.8
Total assets $323.0 $315.2 $313.0 $302.1 $262.7
Long-term debt $85.0 $85.0 $85.2 $90.1 $84.1
Total debt to capitalization 50.3% 51.8% 55.0% 49.7% 48.0%
Shareholders' equity (3) $126.3 $121.3 $114.8 $117.9 $109.0
Book value per common share $24.36 $23.56 $22.31 $23.01 $21.34
GENERAL
Avg. shares outstanding for primary earnings per share (4) 5,259 5,221 5,194 5,172 5,532
Avg. shares outstanding for fully diluted earnings per share (4) - - - 6,363 6,723
Number of employees 1,828 1,927 2,015 2,091 2,084
<FN>
(1) Primary earnings per common share for fiscal 1991 - 1995 are calculated by
dividing net earnings by the average number of common and common equivalents
(stock options) shares outstanding during those fiscal years.
(2) Fully diluted earnings per share in 1991 and 1992 assume conversion of a
convertible subordinated zero coupon note which was convertible into shares
of Class B Common Stock. In 1992, the calculation was antidilutive and in
1993 - 1995, the calculation was not applicable.
(3) Gains and losses resulting from translation (except in foreign countries
experiencing hyperinflation) are reflected as an adjustment to shareholders'
equity.
(4) Average shares outstanding are in thousands.
</TABLE>
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
RESULTS OF OPERATIONS
Summary
Net earnings for fiscal 1995 were $10.7 million ($2.04 per share) compared
with $10.6 million ($2.02 per share) in fiscal 1994. Earnings from continuing
operations in fiscal 1995 were $9.5 million ($1.80 per share) compared with
$8.9 million ($1.71 per share) in fiscal 1994, excluding an after-tax benefit
in 1994 of $2.1 million ($.40 per share) related to the suspension of the
defined benefit portion of the Company's retirement program. The seven percent
increase in earnings from continuing operations was largely due to higher corn
margins in the United States combined with higher sales volumes for each of
the product lines in the United States. Swine earnings decreased
substantially due to lower market hog prices and soft demand for breeding
stock.
Net earnings in fiscal 1994 increased significantly over fiscal 1993 as
earnings from all business segments improved. North American seed earnings
were nearly three times higher than the previous year as corn and soybean
volumes increased and swine earnings nearly doubled due to sales volume
increases. International seed earnings rebounded in fiscal 1994 from
disappointing results in fiscal 1993 when significant losses were recognized
in Spain and Australia.
Fiscal 1995 revenues were $319.4 million, up over six percent from $300.2
million in fiscal 1994. North American seed revenues increased nine percent
and international seed revenues were up 13 percent while swine revenues
decreased ten percent in fiscal 1995. In fiscal 1994, North American seed and
swine revenues increased over ten percent each and international revenues were
lower than the previous year.
During the third quarter of fiscal 1995, the Company sold the stock of its
wholly-owned poultry subsidiary to Central Farm of America, Inc., an
affiliate of Toshoku, LTD., a Tokyo-based trading company specializing in food
and food products. A gain of $1.7 million, after-tax, was recognized as a
result of the sale while discontinued operations reported a loss of $0.5
million, after-tax, for the eight months that the Company owned the subsidiary
in fiscal 1995. Net proceeds of over $9 million in cash were reinvested in
the Company's seed and swine businesses.
The fiscal 1994 suspension of the defined benefit portion of the retirement
plan affected each of the segment's earnings. The benefit, after-tax,
recognized by each segment was: $1.7 million for North American seed and $0.2
million each for swine and corporate. In addition, in fiscal 1994, the Company
adopted financial accounting standard No. 109 (SFAS), "Accounting for Income
Taxes." The adoptions of SFAS No. 109 resulted in the recognition of $0.4
million ($.09 per share) of deferred tax expense.
<PAGE>
Fourth Quarter
The fourth quarter net loss of $1.2 million ($.23 per share) was in sharp
contrast to prior fourth quarter earnings of $1.2 million ($.22 per share).
However, the fourth quarter of fiscal 1994 included the recognition of certain
full year foreign royalties due to license contract revisions. Losses are more
typical for DEKALB in the fourth quarter becuse that period primarily reflects
corporate and interest expenses and adjustments related to estimated full year
seed returns and expenses recorded in the previous nine months. The fiscal
1993 fourth quarter loss of $2.8 million reflected a loss on the write-off of
the Comapny's investment in Spain and higher than anticipated seed returns in
the United States.
Industry Segment Revenues and Pre-Tax Earnings
(in millions)
Years ended August 31
1995 1994 1993
Revenues
North American seed $199.9 $183.8 $162.7
International seed 72.1 63.7 69.6
Swine 47.4 52.7 45.1
$319.4 $300.2 $277.4
Pre-tax Earnings
North American seed $22.3 $14.7 $5.2
International seed 7.6 8.0 3.3
Swine (.9) 5.7 3.0
General Corporate Expenses (5.4) (5.7) (5.9)
Interest Expense, Net (8.5) (7.5) (8.2)
$15.1 $15.2 $(2.6)
North American Seed
Segment earnings for North American seed increased 52 percent from $14.7
million in fiscal 1994 to $22.3 million in fiscal 1995 as revenues rose nearly
nine percent. The revenue increase was due to improved corn sales product mix
which created a six percent increase in average corn selling price plus all
five product lines experienced sales volume increases. In fiscal 1994, North
American seed revenues were 13 percent higher than a year earlier. Sales
volume was higher for corn, soybeans, sorghum, alfalfa and sunflowers but corn
average selling price was lower due to a higher portion of small-sized seed in
the product mix sold at lower prices.
Corn sales volume in the United States increased three percent despite a nine
percent decrease in planted acreage in fiscal 1995. The resulting market
share increase of over one percentage point was driven by higher sales in the
Cornbelt. Corn margin also increased over $8 per unit. The combination of a
higher average selling price due to a favorable product mix and a lower cost
per unit caused the margin increase. Cost per unit decreased as the result
of a large production crop harvested in the fall of 1994 following very
favorable growing conditions during the preceding summer. In fiscal 1994,
cost per unit was higher because of a smaller and below-target crop produced
in the summer of 1993.
Soybean sales volume increased over 16 percent in fiscal 1995 compared with
fiscal 1994 largely due to increased demand for the product and higher planted
acreage. In fiscal 1994, sales volume increased 13 percent over fiscal 1993.
The contribution of the soybean product line to segment earnings has continued
to increase over the past three years as the result of growing sales volume.
Unit margins have remained relatively unchanged over this time period.
<PAGE>
Sorghum planted acreage fell for the third year in a row but DEKALB sales
volume increased over six percent in fiscal 1995, following a two percent
increase in fiscal 1994. Cost per unit increased in fiscal 1995 due to
unfavorable production conditions. Margin per unit decreased five percent in
fiscal 1995 due to higher cost and a less favorable sales mix. In fiscal
1994, average selling price was three percent below fiscal 1993 due to a
shift in the sales mix to lower-priced products. Even though volume was
higher in 1994, total sorghum margin and contribution to segment earnings was
lower in that year than in fiscal 1993.
Segment earnings were up significantly in fiscal 1994 compared with fiscal
1993 due to the higher sales volumes combined with lower operating expenses,
including the benefit from the suspension of the retirement program.
International Seed
Segment earnings for international seed were down slightly compared with
fiscal 1994. Revenues were up 13 percent in fiscal 1995 due to increased
sales volumes for all major products in Argentina plus higher export sales
volume. In fiscal 1994, sales volumes in Argentina were down from fiscal 1993
levels and, as a result, revenues were eight percent lower than in fiscal
1993.
Segment earnings from Latin America were mixed as earnings from Argentine
operations increased and equity earnings from Mexico were lower. Argentine
corn operations rebounded from the adverse growing conditions in fiscal 1994
and experienced higher average selling prices and sales volume in fiscal 1995.
These two factors contributed to a substantial improvement in Argentine
earnings. In Mexico, however, drought and the lack of agricultural credit due
to the devaluation of the peso significantly reduced corn sales opportunities.
In addition, seed corn production and discard costs were significantly above
fiscal 1994 levels. The earnings decrease in Mexico more than offset the
improvement in Argentina.
In fiscal 1994, segment earnings from Latin America were lower than in fiscal
1993 due to a reduction in planted acreage in Argentina as the result of
adverse weather conditions in that country. Lower unit margins in Argentina
led to a reduction in earnings. Mexico also contributed less to this segment
in fiscal 1994 than it had in fiscal 1993.
Royalty income from Western Europe was higher in fiscal 1995 than in the
previous year, and the loss from company-owned operations in Italy was nearly
comparable with a year earlier.
Results from Europe in fiscal 1994 were higher than in 1993 when significant
losses from Spain were recognized. Increases were also attributable to
improved results from France and Italy.
Results from other international activities were flat with a year ago while
earnings in fiscal 1994 were up over fiscal 1993 due to increased export and
royalty income and the absence of losses in Australia.
Seed segment earnings will continue to be affected by a variety of factors in
both domestic and international markets including the Company's relative
product performance and competitive market position, weather conditions,
commodity prices, governmental programs and trade policies.
<PAGE>
Swine
A combination of lower market hog prices and soft demand for breeding stock led
to a $6.6 million decrease in swine segment earnings in fiscal 1995 compared
with fiscal 1994. Revenues dropped from $52.7 million in 1994 to $47.4
million in 1995 or ten percent for the year even though breeding stock sales
volume increased 12 percent. Liquidation and consolidation of breeding herds
following a significant drop in the market price during the fall and winter of
fiscal 1995 led to soft demand for DEKALB male genetics. The average market
price received by DEKALB fell over $7.50 per hundred weight ($40.24 in fiscal
1995 from $47.83 in fiscal 1994) or 16 percent. Market-driven prices caused
revenues from the female line of the breeding stock business to be flat, even
though sales volume increased in fiscal 1995.
In fiscal 1994, revenues increased nearly 17 percent as breeding stock sales
volume rose 18 percent over fiscal 1993 levels. Expansion of DEKALB
production facilities increased availability of breeding stock while market
hog revenues remained relatively unchanged as price declines late in the
fiscal year offset increased market hog volume.
The decrease in segment earnings was almost entirely due to the drop in
revenues because operating expenses were flat from year to year, excluding the
benefit in fiscal 1994 related to the suspension of the defined benefit
portion of the retirement program. Segment earnings in fiscal 1994 increased
over fiscal 1993 due to higher sales volumes more than offsetting the
additional costs associated with the new production facilities and higher
feed costs.
General
Net interest expense increased $1.0 million in fiscal 1995 over fiscal 1994 as
a result of higher borrowing rates. Interest expense decreased from fiscal
1993 to fiscal 1994 due to lower rates in fiscal 1994 and reduced cash
requirements for the seed production crop.
The effective tax rate increased to 37% in fiscal 1995 from 27% in fiscal 1994
when income taxes increased from a $3.4 million benefit in fiscal 1993 to a
$4.2 million expense in fiscal 1994. A benefit associated with international
seed losses incurred in 1993 was primarily responsible for the shift from 1993
to 1994. In 1994, tax expense reflected additional benefits from these
international seed losses but were partially offset by the effects of adopting
SFAS No. 109.
Effective in fiscal 1995, the Company began accounting for the translation of
foreign currency in countries formerly considered hyperinflationary in
accordance with the Statement of Financial Accounting Standards No. 52 (SFAS
No. 52), "Foreign Currency Translation." The change to SFAS No. 52 accounting
combined with the devaluation of the Mexican peso resulted in a significant
write-down of the Company's investment in its equity position in Mexico. The
resulting translation adjustment of $3.1 million was recorded in the separately
designated component of shareholders' equity.
Statement of Financial Accounting Standards No. 121 (SFAS No. 121) "Accounting
for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be
Disposed Of" is not required to be adopted until fiscal 1997. The Company
does not believe that adoption will have any material impact on its financial
statements.
<PAGE>
FINANCIAL POSITION
Management believes its operating cash flow and existing credit facilities are
sufficient to cover normal and expected working capital needs, dividends,
capital expenditures and debt maturities.
Cash Flow
Net cash flow from operating activities decreased $26.1 million in fiscal
1995. Increased cash was required in fiscal 1995 for the large seed crop
produced in the summer of 1994. Company cash investments in fixed assets were
partly offset by cash generated from the sale of its poultry business. The
net result reduced cash required for investing activities by over $10 million.
In fiscal 1994, the net cash flow from operations of $32.8 million compared
favorably with the $23.0 million of cash outflow in the prior year. Fiscal
1993 included $13.1 million of cash interest related to the prepayment of zero
coupon notes. In April and July of fiscal 1993, the Company prepaid the $50.0
million outstanding principal balance and $13.1 million of amortized interest
on zero coupon notes held by Pfizer, Inc. The financing for the prepayment
was provided by a consortium of lending institutions. By substituting other
financing for the convertible notes, DEKALB lowered the effective interest
rate and eliminated the shareholder dilution that would have resulted from
conversion of the notes. In addition, significant cash was required in fiscal
1993 to build seed inventory levels in the United States and Argentina.
Fiscal 1994 cash flow benefited from increased earnings resulting from higher
sales volumes.
Cash requirements for investing activities were slightly higher in fiscal 1994
than in fiscal 1993 due to increased capital expenditures related to upgrading
seed plants and additional swine production facilities. Net cash outflow from
financial activities included $10.1 million of debt repayment in fiscal 1994.
Credit Facilities
Genetics has various credit facilities and available lines of credit with
several commercial banks, both domestic and foreign. Committed credit lines
include a $50 million revolving credit facility available through December 31,
1997 and $20 million in credit facilities for a 364 day period.
The revolving credit agreement provides credit for general corporate purposes
and is committed through December 31, 1997, but may be extended annually for
successive one year periods with the consent of the lending banks. This line
of credit requires a step-down to $20.0 million for any one day during each
year. The agreement contains various restrictions on the activities of the
Company as to maintenance of working capital and tangible net worth, amount
and type of indebtedness, and the acquisition or disposition of capital shares
or assets of the Company and its subsidiaries. At August 31, 1995, tangible
net worth was approximately $11.3 million in excess of the required minimum
under the most restrictive of these covenants.
Genetics also has numerous uncommitted short term credit facilities available
and draws upon them periodically, including during the twelve months ended
August 31, 1995.
Capital Expenditures
Capital expenditures in fiscal 1995 were $2.7 million less than fiscal 1994.
The Company continued to upgrade and expand seed production plants in the
United States but no additional swine facilities were built in fiscal 1995.
Capital expenditures in 1994 were over $2.0 million higher than the prior year.
The increase was incurred for seed plant expansions in Argentina and the
United States and additional swine production facilities. In each year, the
expenditures were financed with cash generated from operations and short term
financing.
<PAGE>
ITEM 8: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Shareholders and Board of Directors of DEKALB Genetics Corporation:
We have audited the accompanying consolidated balance sheet of DEKALB Genetics
Corporation (a Delaware corporation) and subsidiaries as of August 31, 1995,
and the related consolidated statements of operations and cash flows for the
year then ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audit provides a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of DEKALB Genetics Corporation
and subsidiaries as of August 31, 1995 and the results of their operations and
their cash flows for the year then ended in conformity with generally accepted
accounting principles.
Our audit was made for the purpose of forming an opinion on the basic
financial statements taken as a whole. The schedules listed in Item 14(a)(2)
of this Form 10-K are presented for purposes of complying with the Securities
and Exchange Commissions rules and are not part of the basic financial
statements. These schedules have been subjected to the auditing procedures
applied in the audit of the basic financial statements and, in our opinion,
fairly state in all material respects the financial data required to be set
forth therin in relation to the basic financial statements taken as a whole.
ARTHUR ANDERSEN LLP
Chicago, Illinois
October 6, 1995
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Shareholders and Board of Directors of DEKALB Genetics Corporation:
We have audited the accompanying consolidated balance sheets of DEKALB
Genetics Corporation as of August 31, 1994, and the related consolidated
statements of operations and cash flows for the years ended August 31, 1994
and 1993. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of DEKALB Genetics
Corporation as of August 31, 1994, and the consolidated results of its
operations and its cash flows for the years ended August 31, 1994 and 1993, in
conformity with generally accepted accounting principles.
As discussed in Note L, effective September 1, 1993, the Company adopted the
liability method of accounting for income tax. As discussed in Note A, the
Company changed the accounting method of valuing its commercial seed
inventories and retroactively restated all years presented.
Coopers & Lybrand L.L.P.
Chicago, Illinois
October 12, 1994, except for Note S, as to which the date is October 6, 1995.
<TABLE>
DEKALB Genetics Corporation
CONSOLIDATED STATEMENTS OF OPERATIONS
<CAPTION>
for the years ended August 31--
in millions except per share amounts Note 1995 1994 1993
<S> <C> <C> <C> <C>
Revenues $319.4 $300.2 $277.4
Cost of revenues 162.3 163.9 140.2
Gross Margin 157.1 136.3 137.2
Selling expense 64.5 58.0 58.5
Research and development expense 41.2 40.0 40.4
General and administrative expense 25.8 17.0 27.8
131.5 115.0 126.7
Operating Earnings 25.6 21.3 10.5
Interest expense, net B (8.5) (7.5) (8.2)
Other income (expense), net B (2.0) 1.4 (4.9)
Earnings from continuing operations before income taxes
and accounting change 15.1 15.2 (2.6)
Income tax provision (benefit) A & L 5.6 4.2 (3.4)
Earnings from continuing operations before cumulative
effect of accounting change 9.5 11.0 0.8
Discontinued Operations:
Gain (Loss) from operations, net of tax (0.5) - 0.9
Gain on disposition, net of tax 1.7 - -
Earnings before cumulative effect of accounting change $10.7 $11.0 $1.7
Cumulative effect of accounting change - (0.4) -
NET EARNINGS $10.7 $10.6 $1.7
Earnings per share from continuing operations before
cumulative effect of accounting change $1.80 $2.11 $0.15
Discontinued Operations:
Gain (Loss) from operations, net of tax (0.09) - 0.18
Gain on disposition, net of tax 0.33 - -
Earnings per share before cumulative effect of
accounting change $2.04 $2.11 $0.33
Cumulative effect of accounting change - (0.09) -
NET EARNINGS PER SHARE $2.04 $2.02 $0.33
DIVIDENDS PER SHARE $0.80 $0.80 $0.80
<FN>
The accompanying notes are an integral part of the financial statements.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
CONSOLIDATED BALANCE SHEETS
<CAPTION>
at August 31--in millions Note 1995 1994
<S> <S> <C> <C> <C>
Assets Current assets:
Cash and cash equivalents A $3.0 $6.2
Receivables, net C 57.6 44.4
Inventories D 106.0 99.4
Deferred income taxes A & L 4.7 4.3
Other current assets 3.7 7.0
Total current assets 175.0 161.3
Investments and advances 3.9 8.0
Intangible assets, net A 40.0 41.3
Other assets 4.3 8.9
Property, plant and equipment, net A & E 99.8 95.7
Total Assets $323.0 $315.2
Liabilities and Shareholders' Equity:
Current liabilities:
Short-term debt $42.8 $45.1
Accounts payable, trade 6.7 6.4
Other accounts payable 15.6 13.2
Other current liabilities F 29.5 27.7
Total current liabilities 94.6 92.4
Deferred compensation and other credits 5.8 5.4
Deferred income taxes A & L 11.3 11.1
Long-term debt H 85.0 85.0
Total long-term liabilities 102.1 101.5
Commitments and contingent liabilities K
Shareholders' equity: J
Capital stock:
Common, Class A; no par value,
authorized 5,000,000 shares,
issued 772,942 and 787,639
for 1995 and 1994, respectively 0.1 0.1
Common, Class B; no par value,
non-voting, authorized 15,000,000
shares issued 4,484,882 and 4,431,387
for 1995 and 1994, respectively 0.4 0.4
Capital in excess of stated value 80.9 80.1
Retained earnings 52.3 45.8
Cumulative translation adjustment (5.0) (2.7)
128.7 123.7
Less treasury stock, at cost: 782 shares of Class A
in 1995 and 73,201 shares of Class B in 1995 and 1994. (2.4) (2.4)
Total shareholders' equity 126.3 121.3
Total Liabilities and Shareholders' Equity $323.0 $315.2
<FN>
The accompanying notes are an integral part of the financial statements.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
CONSOLIDATED STATEMENTS OF CASH FLOWS
<CAPTION>
For the years ended
August 31--in millions
1995 1994 1993
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings $10.7 $10.6 $1.7
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization 11.1 10.8 10.4
Interest on zero coupon note - - 3.1
(Gain) loss on sale of fixed assets (0.5) (1.3) 0.1
Provision for losses on accounts receivable 0.6 0.7 1.0
Provision for deferred income taxes 1.0 1.1 (6.3)
Provision for inventory valuation 10.6 10.1 9.7
Loss on divestiture of foreign subsidiaries - - 6.1
Equity (earnings) loss, net of dividends 1.0 (0.1) (0.4)
Cumulative effect of accounting change - 0.4 -
Loss from discontinued operations 0.5 - -
Gain from disposition of discontinued operations (1.7) - (0.9)
22.6 21.7 22.8
Changes in assets and liabilities:
Receivables (13.8) (11.3) (4.6)
Other current assets 0.6 - 2.1
Inventories (17.2) 6.8 (27.9)
Accounts payable 2.7 8.3 (4.9)
Accrued expenses 1.6 (1.8) 1.3
Current taxes payable (1.1) - 1.8
Deferred income taxes (0.9) (1.5) 0.2
Other assets and liabilities 1.5 - (2.4)
Interest associated with prepayment of zero coupon notes - - (13.1)
(26.6) 0.5 (47.5)
Net cash flow provided (used) by operating activities 6.7 32.8 (23.0)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment (15.4) (18.1) (15.5)
Proceeds from sale of property, plant and equipment 1.2 1.8 0.8
Proceeds from sale of discontinued operations 12.5 - -
Cash provided (used) by discontinued operations (3.5) 0.4 2.3
Net cash flow used by investing activities (5.2) (15.9) (12.4)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuing debt - - 84.5
Principal payments made on debt (2.3) (10.1) -
Prepayment of zero coupon notes - - (50.0)
Dividends paid (4.2) (4.1) (4.1)
Other capital transactions 0.8 0.2 0.4
Net cash flow provided (used) by financing activities (5.7) (14.0) 30.8
Net effect of exchange rates on cash 1.0 (0.2) (1.3)
Net increase (decrease) in cash and cash equivalents (3.2) 2.7 (5.9)
Cash and cash equivalents, at the beginning of the year 6.2 3.5 9.4
Cash and cash equivalents, at the end of the year $3.0 $6.2 $3.5
Note: Cash paid during the year for:
Income taxes $6.8 $3.3 $1.3
Interest (a) $8.7 $8.1 $18.1
<FN>
(a) In fiscal 1993, included $13.1 million of interest amortization as part of
the prepayment of the zero coupon notes.
The accompanying notes are an integral part of the financial statements.
</TABLE>
<PAGE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A. Accounting Policies
Principles of Consolidation - The consolidated financial statements include
the accounts of the seed division ("DEKALB Seed") and DEKALB Swine Breeders,
Inc. ("DEKALB Swine"). The accounts of Genetic's subsidiary in Argentina are
included on the basis of its May 31 fiscal year, which more properly reflects
the growing season in that country. Transactions between these dates and the
Company's fiscal year-end are not considered material.
The Company's investments in related companies (owned 50% or less),
primarily in Mexico, are carried at cost plus equity in undistributed net
earnings and losses since dates of acquisition. Carrying values approximate
the Company's interest in the net assets of these related companies.
Accounting Change - During the third quarter of fiscal 1994, the Company
changed the accounting method of valuing its commercial seed inventories,
previously valued using the last-in, first-out (LIFO) method, to average cost.
The Company's planning, production and sales activities include the
utilization of commercial seed inventories from more than one crop year.
However, the use of the LIFO method, in effect, caused the matching of the
most recent crop year's cost with current revenues. This caused significant
commercial seed earnings volatility given year-to-year uncertainties such as
crop size, yield and market prices. Therefore, the Company believes the
average cost method of inventory valuation achieves a better matching of
blended inventory costs with revenues and better reflects the utilization of
commercial seed inventory units. The change in accounting method has been
applied retroactively and financial information for all periods presented has
been restated. In fiscal 1994, net earnings were $1.3 million ($.24 per
share) higher as a result of the change and net earnings for fiscal 1993
decreased $1.4 million ($.27 per share).
Intangible Assets- Intangible assets consist primarily of the cost of
purchased businesses in excess of market value of net assets acquired
(goodwill). Genetics amortizes goodwill on a straight-line method over 40
years.
Property, Plant and Equipment - It is the policy of Genetics to capitalize
expenditures for major renewals and betterments and to charge to operating
expenses the cost of current maintenance and repairs. Provisions for
depreciation have been computed principally on the straight-line method, based
on expected lives, for buildings and equipment. Rates used for depreciation
are determined separately for individual plants and locations and are based
principally on the following expected lives: buildings - 12.5 to 33.5 years;
equipment - 4 to 12.5 years; other - 3 to 20 years; and leasehold improvements
- - term of lease or useful life, whichever is shorter.
The cost and accumulated allowances for depreciation and amortization
relating to assets retired or otherwise disposed of are eliminated from the
respective accounts at the time of disposition. The resulting gain or loss is
included in "other income, net".
<PAGE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
Income Taxes - Effective September 1, 1993, the Company changed its method of
accounting for income taxes by adopting the provisions of Statement of
Financial Accounting Standards No. 109 (SFAS No. 109), "Accounting for Income
Taxes." SFAS 109 requires a change from the deferred method of accounting for
income taxes under APB Opinion 11 to the asset and liability method of
accounting for income taxes. Under the asset and liability method, deferred
tax assets and liabilities are recognized for the expected future book and tax
bases of assets and liabilities using enacted tax rates expected to apply in
the years in which the temporary differences are expected to reverse.
The adoption of SFAS 109 resulted in the recognition of $0.4 million,
$.09 per share, of deferred tax expense. This amount was included as a charge
to net earnings as the cumulative effect of change in accounting principle in
the first quarter of fiscal 1994.
Deferred taxes arise principally from temporary differences between
financial and tax reporting. The most significant of these differences are
set forth in Note M. At August 31, 1995, United States income taxes were
provided on all undistributed earnings of non-U.S. subsidiaries.
Foreign Currency Translation - Effective in fiscal 1995, the Company no longer
considers certain countries hyperinflationary for purposes of applying
Statement of Financial Accounting Standards No. 52 (SFAS No. 52), "Foreign
Currency Translation." Foreign-currency assets and liabilities are translated
into their U.S. dollar equivalents based on rates of exchange prevailing at
the end of the respective period. Translation adjustments resulting from
translating foreign currency financial statements of consolidated subsidiaries
into their U.S. dollar equivalents are reported separately and accumulated in
a component of shareholders' equity.
Statement of Cash Flows - Genetics classifies highly liquid investments with
original maturities of three months or less as cash and cash equivalents.
Concentration of Credit Risk - The Company's business activity is primarily
with dealers and distributors located in the United States and certain foreign
countries. When the Company grants credit, it is primarily to customers whose
ability to pay is dependent upon the agribusiness economics prevailing in that
specific area of the world. No significant concentration of credit risk
exists.
Revenue Recognition - The Company recognizes revenues upon shipment of goods,
with discounts and returned goods offsetting this amount.
Reclassifications - Certain expense reclassifications have been made for
segment comparability purposes. These reclassifications had no effect on net
earnings. In addition, during fiscal 1995 the Company began deferring certain
costs associated with its swine licensing business.
Earnings Per Share - Primary earnings per share of common stock are calculated
by dividing net earnings by the weighted average of common and common
equivalent (stock options) shares outstanding during each fiscal year:
5,258,617; 5,221,038 and 5,193,803 in 1995, 1994 and 1993, respectively.
<TABLE>
DEKALB GENETICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
B. Statement of
Operations Data
<CAPTION>
for the years ended August 31--in millions 1995 1994 1993
<S> <S> <C> <C> <C>
(1) Interest Expense,
Net
Interest expense $ (9.6) $ (8.2) $ (8.7)
Interest income 1.1 0.7 0.5
Interest Expense, net $ (8.5) $ (7.5) $ (8.2)
for the years ended August 31--in millions 1995 1994 1993
(2) Other Income,
Net
Equity in net earnings of related companies $ (1.0) $ 1.5 $ 1.8
Foreign exchange gain/losses
--principally translation - 0.1 -
Amortization of goodwill (1.3) (1.4) (1.4)
Loss on divestiture of foreign subsidiaries - - (3.9)
All others, net 0.3 1.2 (1.4)
Other income, net (2.0) 1.4 (4.9)
for the years ended August 31--in millions 1995 1994 1993
(3) Research and
Development Expense
DEKALB Seed $ 35.4 $ 33.6 $ 34.7
DEKALB Swine 5.8 6.4 5.7
Research and development expense $ 41.2 $ 40.0 $ 40.4
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
<CAPTION>
C. Receivables at August 31--in millions 1995 1994
<S> <S> <C> <C>
Trade accounts and notes $53.2 $41.5
Employees 2.3 1.9
Related companies 1.3 1.2
Other 3.5 2.0
60.3 46.6
Less allowance for doubtful accounts 2.7 2.2
Receivables, net $57.6 $44.4
<CAPTION>
D. Inventories at August 31--in millions 1995 1994
<S> <S> <C> <C>
At lower of cost or market:
Commercial seed--average cost $95.3 $88.1
Commercial swine--average cost 7.6 8.1
Supplies and other--principally first-in, 3.1 3.2
Inventories $106.0 $99.4
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
<CAPTION>
E. Property, Plant and at August 31--in millions 1995 1994
Equipment, Net
(at cost)
<S> <S> <C> <C>
Land $9.2 $9.2
Buildings 81.7 76.1
Equipment 127.2 123.1
Other 10.7 10.7
Construction in progress 11.2 11.7
240.0 230.8
Less accumulated depreciation and amortization 140.2 135.1
Property, plant and equipment, net $99.8 $95.7
<CAPTION>
F. Other Current at August 31--in millions 1995 1994
Liabilities
<S> <S> <C> <C>
Current income taxes $0.2 $1.3
Payroll 5.2 6.6
Vacation 2.5 2.4
Pensions and other credits 1.4 0.7
Insurance 2.2 1.9
Taxes, other than income 6.5 4.9
Production costs 2.1 1.5
Other 9.4 8.4
Other current liabilities $29.5 $27.7
</TABLE>
<PAGE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
G. Financial Instruments and Related Disclosures
During 1995, the Company adopted Statement of Financial Accounting Standards
No. 119, "Disclosures About Derivative Financial Instruments and Fair Value
of Financial Instruments". This statement in conjunction with Statement
of Financial Accounting Standards No. 107, "Disclosures About Fair Value of
Financial Instruments" requires certain disclosures about the fair value of
financial instuments, including derivative financial instruments for which
it is practicable to estimate fair value.
The following methods and assumptions were used to estimate the fair market
value of each class of financial instrument.
Trade Accounts and Notes Receivable
The carrying amount of the Company's trade accounts and notes receivable
approximates market value.
Short-term and Long-term Debt
Short-term debt represents borrowings against lines of credit with
various banks. The weighted average interest rate on short-term borrowings
for fiscal 1995 was approximately 6.6%. At August 31, 1995, committed lines
of credit available to Genetics included a $50 million revolving credit
agreement and $20 million in credit facilities for a 364 day period.
The revolving credit agreement provides credit for general purposes and is
committed through December 31, 1997, but may be extended annually for
successive one year periods with the consent of the lending banks. The
line of credit requires a step-down to $20.0 million for any one day during
each year. The agreement contains various restrictions on the activities of
the Company as to maintenance of working capital and tangible net worth,
amount and type of indebtedness and the acquisition or disposition of
capital shares or assets of the Company and its subsidiaries. At August 31,
1995, tangible net worth was approximately $11.3 million in excess of the
required minimum under the most restrictive of these covenants. The
Company pays a commitment fee of 3/16 of 1% for the $50 million line of
credit. The available line of credit at August 31, 1995 was entriely unused.
The $20 million in credit facilities carry a 1/8 of 1% fee on the unused
portion of the commitment. No fees were required to be paid as the line was
fully utilized in fiscal 1995. The carrying amount of the Company's
long-term debt and all the Company's short-term debt approximates market
value because rates on those debt agreements are variable and are set
periodically based on current rates during the year. An exception would be
the $20 million long-term loan which has a fixed rate of 7.15% and a $5
million long-term loan which has a fixed rate of 7.56%. The Company
estimated the market value of its long-term debt by utilizing a discounted
cash flow methodology.
Swap Agreements
The Company has entered into interest rate swap agreements with third parties
to manage interest rate movements on the majority of its variable rate term
debt. At August 31, 1995, the Company had swap agreements with an aggregate
notional principal amount of $60 million and an average interest rate of
5.8%, maturing in fiscal 1997 and fiscal 1998. Any interest rate
differential on these swap agreements is recognized in interest expense, net
over the terms of the agreements. The interest income (expense) related to
swap agreements recognized during 1995, 1994 and 1993 was $0.1 million,
$(1.3) million and $(1.1) million, respectively. The Company is exposed to
credit loss in the event of nonperformance by the other parties to these
agreements. However, the Company does not anticipate nonperformance by any
of those parties. The Company estimated the market value of its interest
rate swap agreements by utilizing a discounted cash flow methodology.
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
G. Financial Instruments and Related Disclosures (Continued)
Derivatives.
Genetics has contractual commitments with seed growers for payments
based on local market corn and soybean commodity prices. To mitigate the
impact of fluctuation in these prices on inventory costs, the Company hedges
these payments by using Chicago Board of Trade corn and soybean futures and/or
option contracts. Growers not priced at the end of August are normally priced
by March, at which time the related futures and/or options contracts are sold.
The Company estimates the timing of grower payment pricing to determine the
futures and option maturities. In addition, the Company hedges its exposure to
price fluctuations in grain used for swine feed. Gains or losses on these hedge
positions are included as a component of the applicable year's inventory. At
August 31, 1995 and 1994, the Company had corn and soybean futures
contracts outstanding with market values of $2.5 million and $14.3 million
respectively. Margin deposits for open futures and/or option contracts are
recorded as other current assets.
Genetics sells market hogs, which are by-products from the production of
breeding animals, to independent processing and packing firms at a premium to
the major market averages. The Company periodically hedges against the
exposure of price fluctuations in these markets. At August 31, 1995 and 1994
the Company had hog futures contracts outstanding with a contract market value
of $1.9 million and $0.8 million, respectively.
The Company reviews potential foreign currency risks on an on-going basis and
is party to forward contracts in the management of its foreign currency
exposure related to royalty income. In order to reduce its exposure to foreign
currency exchange fluctuation related to royalty payments from its French
licensee and export receipts from its Italian subsidiary, the Company utilizes
foreign currency forward contracts with maturities that mirror the anticipated
receipts and payments in October and November. At August 31, 1995 and 1994,
the Company had French franc forward contracts outstanding with an aggregate
contract market value of $9.5 million and $4.6 million, respectively, and
Italian lira forward contracts outstanding with an aggregate contract market
value of $2.8 million and $1.6 million, respectively. Other foreign currency
transactions occur in the Argentine peso and the Canadian dollar.
<CAPTION>
The estimated fair value of the Company's financial instruments was as follows:
<S> <C> <C>
Carrying Fair
at August 31, 1995-in millions Amount Value
Assets:
Cash and marketable securities $3.0 $3.0
Trade accounts and notes receivable 57.6 57.6
Forward exchange contract - -
Open futures contracts (0.2) 0.5
Interest rate swap agreements - 0.2
Liabilities:
Short-term debt 42.8 42.8
Trade accounts payable 6.7 6.7
Long-term debt 85.0 84.7
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
<CAPTION>
H. Long-Term Debt at August 31--in millions 1995 1994
<S> <S> <C> <C>
Term loans, variable rates, due 1998 $60.0 $65.0
Term loans, 7.15% fixed rate, due from 1999-2003 20.0 20.0
Term Loan, 7.56% fixed rated, due from 1999-2005 5.0 -
85.0 85.0
Less current maturities - -
Net long-term debt $85.0 $85.0
<FN>
The variable rate term loan agreements allow the Company
to borrow at rates based on the London Interbank Offer
Rate on Eurodollar deposits (LIBOR). At August 31, 1995,
interest on the variable rate term loans was at a rate of
approximately 6.6%.
All of the term loans contain similar restrictive
covenants. The most restrictive of these covenants
requires the maintenance of a minimum tangible net worth.
At August 31, 1995 the Company's tangible net worth was
approximately $11.3 million in excess of the required
minimum under this covenant. Aggregate maturities for the
years ending August 31, 1998 are $60 million and $4.7
million in each of the years 1999 through 2001. The
remaining $10.9 million matures between 2001 and 2005.
There are no long-term debt maturities in 1996 or 1997.
Current maturities of long-term debt (less than $0.1
million) are included with notes payable in the
consolidated balance sheets.
I. Thrift Plans Full and part-time Genetics' employees can participate
in a voluntary thrift plan (401(k)). The plan provides for
Genetics to contribute a minimum of $.50 for every dollar
contributed by employees, to the extent employees
contribute up to 6% of their salaries. Additional
discretionary amounts may also be contributed when
warranted by results of operations. Genetics'
contributions charged to expense under this plan were
$2.3 million for the year ended August 31, 1995, $1.3
million in 1994 and $1.4 million in 1993.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
<CAPTION>
J. Shareholders'Equity
at August 31--in millions except 1995 1994 1993
shares in thousands Dollars Shares Dollars Shares Dollars Shares
<S> <S> <C> <C> <C> <C> <C> <C>
Class A Common Stock
Balance, beginning of year $0.1 788 $0.1 841 $0.1 862
Exchange Class A for Class B (54) - (60) - (37)
Stock options exercised 34 - 1 - 6
Employee 401(k) stock plan 5 - 6 - 10
Balance, end of year $0.1 773 $0.1 788 $0.1 841
Class B Common Stock
Balance, beginning of year $0.4 4,431 $0.4 4,371 $0.4 4,334
Exchange Class A for Class B 54 - 60 - 37
Balance, end of year $0.4 4,485 $0.4 4,431 $0.4 4,371
Capital in Excess of Stated Value
Balance, beginning of year $80.1 $79.9 $79.4
Stock options exercised 0.6 - 0.1
Employee 401(k) stock plan 0.1 0.1 0.3
Director Stock Option Plan 0.1 0.1 0.1
Balance, end of year $80.9 $80.1 $79.9
Retained Earnings
Balance, beginning of year $45.8 $39.3 $41.7
Net Income 10.7 10.6 1.7
Cash dividends $.80 per share (4.2) (4.1) (4.1)
Balance, end of year $52.3 $45.8 $39.3
Cumulative Translation Adjustment
Balance, beginning of year ($2.7) ($2.5) ($1.2)
Translation gain/(loss) (2.3) (0.2) (1.3)
Balance, end of year ($5.0) ($2.7) ($2.5)
Treasury Stock
Balance, beginning of year ($2.4) (73) ($2.4) (73) ($2.4) (73)
Stock options exercised (0.2) (7) - - - -
Employee 401(k) stock plan 0.2 6 - - - -
Balance, end of year ($2.4) (74) ($2.4) (73) ($2.4) (73)
Total Shareholders' Equity $126.3 $121.3 $114.8
<FN>
The holders of Class A Common Stock and Class B Common Stock have the same
rights in all respects, including rights with respect to dividends and other
distributions, except that (i) the holders of Class B Common Stock have no
voting rights other than as required by the Delaware General Corporation
Law, (ii) the holders of Class A Common Stock may exchange, at their
election, any of their shares for an equal number of shares of Class B
Common Stock on a continuing basis and (iii) the Board of Directors of
Genetics may distribute (A) voting stock of subsidiaries of Genetics to the
holders of Class A Common Stock of Genetics and (B) non-voting stock of
subsidiaries Genetics to the holders of Class B Common Stock of Genetics.
The Company also has 500,000 shares of $1 par value preferred stock
authorized and unissued.
</TABLE>
<PAGE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
K. Commitments and Contingent Liabilities
Genetics is a defendant in various legal actions arising in the course of
business activities. In the opinion of the management, these actions will
not result in a material adverse effect on Genetics' consolidated results of
operations or financial position.
Genetics is self-insured against property losses on the majority of its
operating facilities.
Genetics' total rental expense for fiscal years 1995, 1994 and 1993 was $5.4
million, $4.6 million and $5.1 million, respectively.
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
<CAPTION>
L. Income Tax
for the year ended August 31--in millions 1995 1994 1993
<S> <S> <C> <C> <C>
Current provision:
Federal $1.3 $1.2 $0.2
State 0.7 0.5 0.2
Foreign 2.6 1.5 2.1
$4.6 $3.2 $2.5
Deferred provision:
Federal $1.5 $1.0 ($4.5)
State (0.1) 0.2 (0.9)
Foreign (0.4) (0.2) (0.5)
1.0 1.0 (5.9)
Total income tax provision (benefit) $5.6 $4.2 ($3.4)
The significant components of the company's deferred tax
assets and deferred tax liabilities are presented below:
<CAPTION>
as of August 31-in millions 1995 1994
<S> <S> <C> <C>
Deferred tax assets:
Research Expenditures 6.8 8.0
Benefit Plans 1.7 2.1
Inventory 3.9 3.8
Other 4.6 3.6
Total Gross Deferred Tax Assets 17.0 17.5
Valuation Allowance (0.8) (0.8)
Gross Deferred Tax Assets 16.2 16.7
Deferred Tax Liabilities:
Purchase Price Allocations (9.6) (9.3)
Undistributed Foreign Earnings (5.4) (6.4)
Depreciation (5.1) (5.3)
Other (2.7) (2.5)
Gross Deferred Tax Liabilities (22.8) (23.5)
Net Deferred Tax Liability (6.6) (6.8)
<FN>
The net deferred tax liability disclosed above equals the
net deferred tax presentation on the balance sheet. The
footnote disclosure classifies the components as assets
or liabilities while the balance sheet discloses the
current and long-term portion of those two
classifications. The valuation allowance relates to
those deferred tax assets that may not be fully
realized.
Deferred taxes for 1993 were prepared under A.P.B.
Opinion No. 11 and timing differences in the recognition
of revenue and expenses for tax and financial statement
purposes resulted primarily from depreciation, research
expenditures, and taxes provided on undistributed
earnings of non-U.S. subsidiaries.
Total tax provisions (benefits) resulted in amounts
differing from those based on the statutory federal
income tax rates. The reasons for these differences are:
<CAPTION>
for the years ended August 31--in millions 1995 1994 1993
<S> <S> <C> <C> <C>
U.S. statutory rate $5.3 $5.3 ($0.9)
State and local taxes 0.4 0.4 (0.5)
International operations (0.3) (1.8) (1.5)
Qualified export activity - - (0.1)
Research credits (0.5) (0.3) (0.6)
Other 0.7 0.6 0.2
Income tax provision (benefit) $5.6 $4.2 ($3.4)
<CAPTION>
The domestic and foreign components of earnings before taxes of consolidated companies were as follows:
for the years ended August 31--in millions 1995 1994 1993
<S> <S> <C> <C> <C>
U.S. $13.3 $10.0 ($3.4)
Argentina 2.1 0.7 6.2
Other Non-U.S. (0.3) 4.5 (5.4)
Total earnings before taxes $15.1 $15.2 ($2.6)
<FN>
Effective September 1, 1993, the Company adopted the
liability method of accounting for income taxes under
Statement of Financial Accounting Standards (SFAS) No.
109, "Accounting for Income Taxes". Prior to fiscal
year 1994, income tax was calculated in accordance with
Accounting Principle Board Opinion No. 11. The adoption
of SFAS 109 resulted in a one-time provision adjustment
of $.4 million or $.09 per share which was recorded in
the first quarter of fiscal year 1994. This amount is
included as a charge to net earnings as the cumulative
effect of accounting change.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
M. Quarterly Results of Operations (Unaudited)
The following is a summary of the unaudited quarterly results of operations for
the years ended August 31, 1995 and 1994. Genetics' North American seed
operations comprise a significant portion of its business. Genetics generally
delivers only a minor portion of North American seed in the first quarter,
delivers more than half in the second quarter, and substantially all the seed
is delivered by the end of the third quarter. The Company defers first quarter
expenses and anticipates fourth quarter expenses and matches these expenses
against second and third quarter revenues. Third quarter results also reflect
estimates of seed product returns. Consequently, fourth quarter earnings
include adjustments for those earlier estimates.
The total of four quarters' earnings per share might not equal the earnings per
share for the year due to the application of the treasury stock method and
market price changes.
<CAPTION>
in millions except per share amounts--
three months ended the last day of November February May August
<S> <C> <C> <C> <C>
1995
Revenues $45.2 $144.2 $104.9 $25.1
Cost of Revenues 26.8 71.1 50.6 13.8
Net earnings (1.2) 7.7 5.4 (1.2)
Earnings per share $(0.23) $1.48 $1.02 (0.23)
1994
Revenues $36.2 $138.4 $102.3 $23.3
Cost of Revenues 18.4 77.1 55.8 12.6
Net earnings 0.8 6.4 2.2 1.2
Earnings per share $0.15 $1.23 $0.42 0.22
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
N. Operations by Geographic Area
Information on Genetic's operations by geographic area for fiscal years 1995,
1994 and 1993 is shown below. Operating earnings (loss) are equal to total
revenues less expenses of the geographic areas, excluding interest and general
corporate expenses. Transfers of products between geographic areas are at
prices approximating those charged to unaffiliated customers and are not
material to any geographic area.
<CAPTION>
August 31--in millions 1995 1994 1993
<S> <C> <C> <C>
Revenues
United States $243.2 $232.8 $204.4
Argentina 42.5 37.4 43.4
Other Non-U.S. 33.7 30.0 29.6
$314.5 $300.2 $277.4
Operating Earnings
United States $21.0 $21.9 $9.1
Argentina 5.2 3.0 8.2
Other Non-U.S. 3.8 3.5 (7.6)
$30.0 $28.4 $9.7
Equity in Earnings
Other Non-U.S. ($1.0) $1.5 $1.8
Identifiable Assets
United States $232.1 $225.5 $225.5
Argentina 64.2 54.5 45.6
Other Non-U.S. 26.7 35.2 41.8
$323.0 $315.2 $312.9
<FN>
Consolidated net assets included approximately $35.4 million at August 31, 1995
and $38.3 million at August 31, 1994, located in countries other than the
United States. Consolidated net earnings included approximate earnings of
$1.1 million in fiscal year 1995 and $4.8 million in fiscal year 1994 from
these countries.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
O. Pension Plans
Prior to fiscal 1994, the Company provided employees a noncontributory pension
plan covering substantially all domestic employees who met age and service
requirements. Benefits provided under this pension plan are based primarily
on each employee's career earnings up until the suspension of the plan on
October 1, 1993. Plan assets consist primarily of stocks and U.S. government
securities. At the time of suspension, the Company recognized a pre-tax
curtailment benefit of $3.7 million.
In addition, Genetics has a supplemental noncontributory pension plan covering
certain management employees, which is not funded. Benefits are based mainly
on each participant's years of service, final average compensation, and
estimated benefits received from certain other benefit plans. This plan was
also suspended on October 1, 1993 and the Company recognized a pre-tax benefit
of $0.5 million related to the suspension.
Total pension expense for the funded plan for the year ended August 31, 1993
was $1.7 million. Pension expense for the supplemental pension plan was $0.2
million for the year ended August 31, 1993.
The components of total estimated pension (income) expense for the two plans
are as follows:
<CAPTION>
August 31- in millions
1995 1994 1993
<S> <S> <C> <C> <C>
Service Cost -- benefits earned during the year $ - $0.2 $2.0
Interest cost on projected benefit obligations 0.9 1.0 1.2
Actual return on plan assets (1.6) (0.4) (1.0)
Net amortization and deferral 0.5 (0.8) (0.3)
Income from plan curtailment 0.0 (4.2) -
Net Pension (Income) Expense $(0.2) $(4.2) $1.9
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
<CAPTION>
O.Pension Plans (Continued)
Actuarial assumptions for August 31, 1995 and
August 31, 1994 are as follows:
1995 1994
<S> <C> <C>
Discount rate 7.0% 6.5-7.0%
Return on plan assets 8.5% 8.5%
<CAPTION>
A reconciliation of the funded status to accrued pension expense is as follows:
Funded Plan Unfunded Plan
August 31-in millions 1995 1994 1995 1994
<S> <S> <C> <C> <C> <C>
Actuarial present value of benefits
based on service to date and present
pay levels:
Vested $8.5 $10.7 $0.4 $0.6
Nonvested 1.0 0.4 - -
Accumulated benefit obligation 9.5 11.1 0.4 0.6
Additional amounts related to projected
pay increases - - - -
Projected benefit obligation 9.5 11.1 0.4 0.6
Plan assets at fair market value 9.4 10.7 - -
Plan assets less than
projected benefit obligation (0.1) (0.4) (0.4) (0.6)
Unrecognized loss
from experience 2.5 2.8 - -
Unrecognized net transition asset (2.8) (3.1) - (0.1)
Accrued pension expense included
in the Consolidated Balance Sheet ($0.4) ($0.7) ($0.4) ($0.7)
<FN>
The Company has obligations under termination indemnification plans in several
foreign countries, but does not have any foreign defined benefit pension plans
as defined in Financial Accounting Standard No. 87.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
P. Information on Related Companies
The following is summarized financial information for Genetics' less than 50
percent owned operations:
<CAPTION>
Balance Sheets
at August 31--in millions 1995 1994
<S> <S> <C> <C>
ASSETS
Current assets $ 8.4 $20.3
Non-current assets 3.9 3.1
Total Assets $12.3 $23.4
LIABILITIES
Current liabilities $2.8 $5.8
Non-current liabilities 1.9 1.4
Total Liabilities $4.7 $7.2
Summary of Earnings
for the years ended August 31--in millions 1995 1994 1993
<S> <S> <C> <C> <C>
Revenues $13.3 $18.4 $21.2
Gross Profit $4.1 $3.5 $4.3
Net Earnings ($2.1) $3.1 $3.5
Genetics' Equity in Net Earnings ($1.0) $1.5 $1.8
<FN>
Genetics' investments in related companies are carried at cost plus equity in
undistributed net earnings and losses since dates of acquisition. Carrying
values approximate Genetics' interest in the net assets of these related
companies. Dividends received from related companies were $1.5 million
in fiscal years 1994 and 1993. No dividends were received in fiscal year 1995.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
Q. Incentive Plans
In August, 1988, the Company adopted a Long-Term Incentive Plan which provides
for the awarding of stock appreciation rights (SARs), stock indemnification
rights (SIRs) and restricted stock and the granting of incentive and
nonqualified options to purchase Class A or Class B Common Stock of the Company.
The Company's Stock Option Committee may make awards of SARs, SIRs, restricted
stock or stock options to certain officers and key employees of the Company.
All stock options may be granted at no less than fair market value of the
Company's stock at the date of grant and are exercisable within periods
specified by the Stock Option Committee.
<CAPTION>
1995 1994 1993
Average Average Average
Class A Price Class A Price Class A Price
<S> <C> <C> <C> <C> <C> <C>
Shares under option
at beginning of year 243,511 $22.50 207,840 $21.85 167,792 $19.76
Activity:
Granted 57,750 27.24 46,400 26.75 48,050 27.87
Exercised (48,623) 24.96 (2,605) 25.29 (6,102) 8.79
Cancelled (15,484) 29.34 (8,124) 29.32 (1,900) 31.63
Shares under option
at end of year 237,154 $22.70 243,511 $22.50 207,840 $21.85
Shares available for
future grants as of August 31 62,317 104,583 142,859
Shares vested and
exercisable as of August 31 150,462 157,561 134,994
<FN>
In fiscal 1991, the shareholders also approved a Director Stock Option Plan
which gives outside directors an election to receive options to purchase Class
A Common Stock (which options have a discounted exercise price) in lieu of
annual retainer and meeting fees. The 25% discount in the exercise price,
multiplied by the number of shares subject to the option, equals the annual
retainer and meeting fees the directors would have received.
Total expense for the Director Stock Option Plan was $.1 million in each of the
fiscal years 1995, 1994 and 1993.
<CAPTION>
1995 1994 1993
Average Average Average
Class A Price Class A Price Class A Price
<S> <C> <C> <C> <C> <C> <C>
Shares under option
at beginning of year 49,079 $22.11 34,348 $21.61 18,759 $22.86
Activity:
Granted 14,685 20.44 14,866 23.25 15,589 20.11
Exercised (9,620) 22.21 0 - 0 -
Cancelled (232) 23.25 (135) 20.07 0 -
Shares under option
at end of year 53,912 $21.63 49,079 $22.11 34,348 $21.61
Shares available for
future grants as August 31 33,404 47,857 62,588
Shares vested as of August 31 53,912 49,079 34,348
Shares exercisable
as of August 31 39,227 34,213 18,759
</TABLE>
<PAGE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
R. Industry Segment
The following industry segment information summarizes Genetics' operations as
of and for the years ended August 31, 1995, 1994, and 1993.
Operating earnings are total sales and revenues less operating expenses of the
segments, excluding interest, and general corporate allocations. No customer
accounted for 10 percent or more of total operating revenues.
<TABLE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, continued
R. Industry Segment
(continued)
<CAPTION>
August 31-in millions 1995 1994 1993
<S> <C> <C> <C>
Revenues
Seed (1) $272.0 $247.5 $232.3
Swine 47.4 52.7 45.1
$319.4 $300.2 $277.4
Earnings (Loss) Before Income Taxes
Seed:
Operating earnings $30.9 $21.2 $6.7
Equity in net earnings of related companies (1.0) 1.5 1.8
29.9 22.7 8.5
Swine (0.9) 5.7 3.0
Total Operations 29.0 28.4 11.5
General corporate expenses (5.4) (5.7) (5.9)
Net interest expense (8.5) (7.5) (8.2)
$15.1 $15.2 ($2.6)
Identifiable Assets
Seed $290.5 $274.0 $274.9
Swine 31.7 34.0 30.3
Discontinued Operations 0.8 7.2 7.7
$323.0 $315.2 $312.9
Depreciation and Amortization Expense
Seed $7.3 $8.4 $8.3
Swine 2.4 2.4 2.1
$9.7 $10.8 $10.4
Property Additions
Seed $14.6 $13.1 $10.2
Swine 0.8 5.0 5.3
$15.4 $18.1 $15.5
<FN>
(1) Consolidated revenues do not include approximately $130 million in fiscal
year 1995, $135 million in fiscal year 1994 and $120 million in fiscal year
1993 of DEKALB seed sold nder royalty agreements with non-consolidated
affiliates and licensees or recognized by equity companies.
(Footnote P)
</TABLE>
<PAGE>
DEKALB Genetics Corporation
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS, Continued
S. Discontinued Operations
On April 28, 1995, the Company sold its poultry operations to Central Farm of
America, Inc., an affiliate of Toshoku, Ltd., for $12.5 million cash.
Accordingly, the poultry business is reported as a discontinued operation and
the consolidated financial statements have been reclassified to report
separately the net assets and operating results of the business. The Company's
operating results for prior years have been restated to reflect continuing
operations.
Net earnings from discontinued operations included an operating loss of $0.5
million, net of $0.5 million tax benefit and a net gain on the sale of $1.7
million, net of $0.5 million tax expense. Revenues for discontinued
operations were $12.1 million for the eight months of fiscal 1995 and $19.8
million for the twelve months of fiscal 1994. Net assets of the discontinued
operations at August 31, 1995 consist primarily of current assets amounting to
$0.8 million.
<PAGE>
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
NONE.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The Company will file with the Securities and Exchange Commission a
definitive Proxy Statement not later than 120 days after the close of its
fiscal year ended August 31, 1995. The information required by this Item is
incorporated by reference from the Proxy Statement.
Information about Executive Officers is shown on page 9 of this filing.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item is incorporated by reference from
the Proxy Statement.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this Item is incorporated by reference from
the Proxy Statement.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this Item is incorporated by reference from
the Proxy Statement.
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a)(1) Financial Statements
The following financial statements of DEKALB Genetics Corporation are
included in Part II, Item 8:
Page
Report of Independent Accountants 17-18
Consolidated Statements of Operations for the years ended
August 31, 1995, 1994 and 1993 19
Consolidated Balance Sheets at August 31, 1995 and 1994 20
Consolidated Statements of Cash Flows for the years ended
August 31, 1995, 1994 and 1993 21
Notes to Consolidated Financial Statements 22-41
(a)(2) Financial Statement Schedules
Page
Report of Independent Accountants 48
Schedule VIII -Valuation and Qualifying Account 49
Schedule X -Supplementary Income Statement Information 50
<PAGE>
Part IV
(a)(3) Exhibits Page
3A Restated Certificate of Incorporation *
of DEKALB Genetics Corporation [Attached
as Exhibit A to Information Statement
contained in Form 8 Amendment (Amendment
No. 3) dated August 18, 1988, amending
Form 10 Registration Statement of the
Company dated June 17, 1988
(File No. 0-17005)]
3B By-Laws of DEKALB Genetics Corporation *
[Attached as Exhibit B to Information Statement
contained in Form 8 Amendment (Amendment
No. 3) dated August 18, 1988, amending
Form 10 Registration Statement of the
Company dated June 17, 1988
(File No. 0-17005)]
4A Form of Class A Common Stock Certificate *
[Incorporated by reference to Exhibit 4A
to Form 8 Amendment (Amendment No. 1)
dated August 3, 1988, amending Form 10
Registration Statement of the Company
dated June 17, 1988 (File No. 0-17005)]
4B Form of Class B Common Stock Certificate *
[Incorporated by reference to Exhibit 4B
to Form 8 Amendment (Amendment No. 1)
dated August 3, 1988, amending Form 10
Registration Statement of the Company
dated June 17, 1988 (File No. 0-17005)]
4C Revolving Credit Agreement between DEKALB *
Genetics Corporation and the banks listed
therein. [Attached as Exhibit 4C to Form 10-K
filed October 14, 1994 (File No. 0-17005)].
Other instruments with respect to long-term debt of
the Registrant are not filed because the total
amount of securities authorized under each such
instrument does not exceed 10% of the total assets
of the Registrant and its subsidiaries on a
consolidated basis and the Company agrees to
provide a copy to the Commission upon request.
<PAGE>
(a)(3) Exhibits
(continued)
10A DEKALB Genetics Corporation Long- *
Term Incentive Plan [Incorporated
by reference to Exhibit 4A to Form S-8
Registration Statement No. 33-24875]**
10B Form of Indemnification Agreements *
[Attached as Exhibit D to Information Statement
contained in Form 8 Amendment (Amendment
No. 3) dated August 18, 1988, amending
Form 10 Registration Statement of the
Company dated June 17, 1988
(File No. 0-17005)]**
10C DEKALB Genetics Corporation Savings and *
Investment Plan [Incorporated by reference
to Exhibit 4.3 to Form S-8 (File No. 33-33305)
dated February 1, 1990]**
10D DEKALB Genetics Corporation Pension Plan** *
10E Form of Long-Term Incentive Plan Agreement *
[Incorporated by reference to Exhibit 4B to
Form S-8 Registration Statement
(Registration No. 33-24875)]**
10F Director Stock Option Plan *
[Incorporated by reference to Exhibit 4.3 to
Form S-8 Registration Statement (Registration
No. 33-39986)]**
10G Employment Agreement between DEKALB Genetics *
Corporation and Bruce P. Bickner
dated September 1, 1994 [Incorporated by
reference to Exhibit 10A to Form 10-Q filed
April 12, 1995 (File No. 0-17005)].**
10H Employment Agreement between DEKALB *
Genetics Corporation and Richard O. Ryan
dated September 1, 1994 [Incorporated by
reference to Exhibit 10B to Form 10-Q filed
April 12, 1995 (File No. 0-17005)].**
10I Employment Agreement between DEKALB Genetics *
Corporation and John H. Witmer, Jr.
dated September 1, 1994 [Incorporated by
reference to Exhibit 10C to Form 10-Q filed
April 12, 1995 (File No. 0-17005)].**
<PAGE>
(a)(3) Exhibits
(continued)
10J Employment Agreement between DEKALB Genetics 51-57
Corporation and Richard T. Crowder
Dated October 26, 1994**
10K Employment Agreement between DEKALB Genetics *
Corporation and Roy L. Poage
dated September 1, 1994 [Incorporated by
reference to Exhibit 10D to Form 10-Q filed
April 12, 1995 (File No. 0-17005)].**
11 Computation of Earnings Per Share 58
21 Subsidiaries of DEKALB Genetics Corporation 59
23A Consent of Independent Accountants
- Arthur Andersen LLP 60
23B Consent of Independant Accountants
- Coopers and Lybrand L.L.P. 61
27 Financial Data Schedule _
* Document has heretofore been filed with the
Commission and is incorporated by reference.
** Document is a management contract or compensating
plan or arrangement.
(b) Reports on Form 8-K - In a report dated June 9, 1995, DEKALB
reported the engagement of new external auditors.
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
DEKALB GENETICS CORPORATION
Date: October 10, 1995 By: Bruce P. Bickner
Bruce P. Bickner
Chairman, Chief Executive Officer
and Director
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities on this 12th day of October, 1995.
Signature Title
Richard O. Ryan President, Chief Operating Officer
Richard O. Ryan and Director
Thomas R. Rauman Vice President - Finance and
Thomas R. Rauman Chief Financial Officer
DIRECTORS
Charles J. Arntzen Allan Aves
Charles J. Arntzen Allan Aves
Paul H. Hatfield
Tod R. Hamachek Paul H. Hatfield
Douglas C. Roberts John T. Roberts
Douglas C. Roberts John T. Roberts
H. Blair White
H. Blair White
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Stockholders and Board of Directors of DEKALB Genetics Corporation:
Our report on the consolidated financial statements of DEKALB Genetics
Corporation is included elsewhere in this Form 10-K. In connection with our
audits of such financial statements, we have also audited the related
financial statement schedules listed in Item 14 (a) of this Form 10-K.
In our opinion, the financial statement schedules referred to above, when
considered in relation to the basic financial statements taken as a whole,
present fairly, in all material respects, the information required to be
included therein.
COOPERS & LYBRAND L.L.P.
Chicago, Illinois
October 12, 1994, except for Note S, as to which the date is October 6, 1995
<TABLE>
DEKALB Genetics Corporation
SCHEDULE VIII - VALUATION and QUALIFYING ACCOUNT
years ended August 31, 1995, 1994 and 1993
<CAPTION>
(Dollars in thousands)
Column A Column B Column C Column D Column E
Additions
Balance at Charged to Charged to Balance at
Beginning Costs and Other End
Description of Period Expenses Accounts Deductions Of Period
<S> <C> <C> <C> <C> <C>
Year ended August 31, 1995:
Deducted in the balance sheet
from the assets to which they
apply:
Allowance for doubtful accounts
and notes receivable $2,159 $961 $0 $407 (a) $2,713
Year ended August 31, 1994:
Deducted in the balance sheet
from the assets to which they
apply:
Allowance for doubtful accounts
and notes receivable $1,537 $725 $0 $103 (a) $2,159
Year ended August 31, 1993:
Deducted in the balance sheet
from the assets to which they
apply:
Allowance for doubtful accounts
and notes receivable $1,407 $883 $62 $815 (a)(b) $1,537
<FN>
Notes:
(a) Uncollectible items written off, less recoveries of items previously
written off.
(b) Includes $426 for the effect of the divestiture of Spain.
</TABLE>
<TABLE>
DEKALB Genetics Corporation
SCHEDULE X - SUPPLEMENTARY INCOME STATEMENT INFORMATION
years ended August 31, 1995, 1994 and 1993
<CAPTION>
(Dollars in thousands)
Column A Column B
Charged to Costs
Description and Expenses
1995 1994 1993
<S> <C> <C> <C>
1.Maintenance and repairs $4,259 $3,727 $4,467
5.Advertising costs $8,918 $8,220 $7,435
<FN>
Note:
Items 2,3 and 4 have been omitted as the amount did not exceed one percent of
total sales and revenues.
</TABLE>
EMPLOYMENT AGREEMENT
THIS AGREEMENT is entered into effective October 26, 1994, between
Richard T. Crowder ("Employee") and DEKALB Genetics Corporation
(the "Company").
1. Employment.
A. The Company agrees to employ Employee in a managerial capacity,
and agrees to be so employed by the Company, for a term commencing
October 26, 1994, Employee and ending on August 31, 1995.
B. This Agreement will be extended for an additional one year period
beginning September 1, 1995, or any September 1st thereafter unless the
Company or the Employee gives the other party notice to the contrary on
or before August 31, 1995 or any August 31st thereafter.
2. Best Efforts of Employee.
A. Employee agrees at all times and to the best of his ability to
perform all of the duties that may be required of him pursuant to the
express and implicit terms of this Agreement to the reasonable
satisfaction of the Company. Such duties shall be rendered at DeKalb,
Illinois or at such other place or places within or without the State
of Illinois as the Company shall in good faith require.
B. Employee shall devote his normal and regular business time,
attention, knowledge and skill to the business and interests of the
Company, and the Company shall be entitled to all of the benefits or
profits arising from or incident to all work, services and advice of
Employee performed for the Company.
3. Annual Compensation.
A. The compensation to be paid to Employee shall be as described in
Exhibit A. Since this Agreement shall remain in effect until amended or
terminated, a new Exhibit A shall be prepared, signed by the parties
and attached to this Agreement on a yearly basis; provided, however, if
Employee resigns his employment because the Company proposes a combined
total of base salary and a reasonably determined performance bonus
target that is more than 10 percent below the prior year's level,
Employee shall be deemed to have been constructively discharged and
entitled to be compensated as though Employee were terminated for other
than cause. In and entitled to be compensated as though Employee were
terminated for other than cause. In such case, Employee's severance
and any other compensation shall be based upon the most recently signed
Exhibit A. The provisions contained in the existing Exhibit A
(including the level of base pay and bonus targets) shall remain in
effect until a new Exhibit A has been signed by the parties. This
Agreement and the applicable Exhibit A shall be treated as one
agreement.
B. Employee's rights under any employee benefit plan (e.g., the
Savings and Investment Plan) or incentive compensation plan (e.g., the
Long-Term Incentive Plan) provided by the Company shall not be affected
by this Agreement.
C. The Company shall pay Employee's reasonable airline fares, hotel
bills and other necessary and proper expenses when traveling or
otherwise performing the Company's business, provided that Employee
promptly furnishes the Company with appropriate supporting
documentation of such expenses.
4. Solicitation of Employees. For a period of three (3) years after he is
no longer employed by the Company, Employee will not, directly or in
directly, either as an individual, proprietor, stockholder, partner,
officer, director, employee or otherwise, solicit any officer,
director, employee or other individual:
A. to leave his or her employment or position with the Company,
B. to compete with the business of the Company, or
C. to violate the terms of any employment, noncompetition or similar
agreement with the Company.
For purposes of this Paragraph 4, references to the business of the
Company shall include the business of any subsidiary or affiliate of
the Company.
5. Confidentiality. Employee will not at any time during or after his
employment by the Company, directly or indirectly, disclose, other than
in the normal course of performing Employee's duties for the Company, any
information concerning any matter affecting or relating to the Company or
the business of the Company. Employee agrees to the foregoing without
regard to whether all of the foregoing matters will be deemed confidential,
material or important, it being agreed that all information, whether
written or otherwise, regarding the Company's business, including but not
limited to, information regarding customers, employees, costs, prices,
financial reports, products, services, research programs, pedigrees,
compositions, patents, equipment, systems, production procedures,
operations, potential acquisitions, new location plans, prospective and
executed contracts and other business arrangements, and sources of supply,
is presumed to be important, material and confidential information of the
Company for purposes of this Agreement, except to the extent that such
information may be otherwise lawfully and readily available to the general
public. Employee further agrees that he will, upon termination of his
employment with the Company, return to the Company all books, records,
lists and other written, typed or printed materials, including information
in computers or computer disks, whether furnished by the Company or
prepared by the Employee, which contain any information relating to the
Company's business, and Employee agrees that he will neither make nor
retain any copies of such materials after termination of employment. For
purposes of this Paragraph 5, references to the business or information of
or relating to the Company shall include the information or business of any
subsidiary or affiliate of the Company.
6. Business Opportunities and Inventions.
A. Employee shall make full and prompt written disclosure to
the Company or its nominee of any business opportunity of which
he becomes aware and which relates to the business of the
Company or any of its subsidiaries or affiliates; and
B. All inventions, discoveries, ideas, improvements and
designs made or conceived by Employee, and copyrights to all
software, writings or other materials prepared by Employee, in
each case solely or with others, while employed by the Company,
during or after working hours, which are useful in or related to
the actual or anticipated business, work or investigations of
the Company, belong exclusively to the Company. Employee shall
disclose to the Company immediately and fully any such
invention, discovery, idea, improvement, design or copyright.
At the request and expense of the Company, either before or
after termination of employment, Employee shall execute a
written assignment of and shall assist in acquiring and
maintaining patent protection upon and confirming the Company's
rights to such inventions, ideas, improvements, designs or
copyrights.
7. Noncompetition Covenant.
A. Employee covenants and agrees that for a period extending
until 12 months after the effective date of the termination of
Employee's employment with the Company hereunder (whether such
termination shall have been voluntary or involuntary on the part
of the Employee), Employee will not directly or indirectly,
either individually or as an employee, agent, partner,
shareholder, director, officer, consultant or in any other
capacity, participate in or have any employment, consultant,
financial, management or other interest in any business
enterprise anywhere in the world that engages in (or within 12
months of the termination of Employee's employment has plans to
engage in) substantial and direct competition with any business
operation actively conducted by the Company or it subsidiaries
or affiliates, or any of their successors or assigns, if the
Employee actively participated in such business operation of the
Company or had awareness of such business operation of the
Company during Employee's employment. The ownership of less
than one percent of the outstanding debt or equity in a
corporation whose shares are traded on a recognized stock
exchange or in the over-the-counter market, even though that
corporation may be a competitor of the Company or any of its
affiliates or subsidiaries, shall not constitute a breach of
this Agreement.
B. The Company shall pay Employee one month's base pay and
one-twelfth of his target bonus (both at the rate in effect on
Employee's termination date) for every one month during the
noncompetition period; provided that, the Company shall make
such payments to Employee pursuant to this Subparagraph 7(B) in
addition to any amount paid pursuant Paragraph 3 or 8 of this
Agreement.
C. Employee agrees that the period of time and the geographic
scope specified with respect to Employee's aforesaid covenant
not to compete is the minimum period of time and geographic area
necessary to reasonably and adequately protect the Company and
its affiliates in the continued operation of their business and
affairs. Employee further acknowledges that the compensation
provided in Subparagraph 7(B) hereof will adequately compensate
Employee during his transition to new employment.
D. If and to the extent that any part of the noncompetition
covenant set forth above shall be deemed by the court in which
a suit is brought to be unenforceable as written, by reason of
it scope in terms of area or length of time, but may be made
enforceable by reducing the area or period of time applicable to
such covenant, Employee and the Company stipulate and agree that
such covenant shall automatically be deemed to be amended for
all purposes of such suit so as to incorporate the aforesaid
reduction in area, or duration of time, or both, to the end
of that such covenant, as modified in connection with such suit,
shall be enforceable to the fullest extent permissible in such
jurisdiction.
E. Employee and the Company acknowledge that there may be
times when the Company may consider it to be appropriate to
waive all or part of the agreement that Employee not compete
with the Company. In such event, the Company may, at its
option, waive all or part of the time period specified in
Subparagraph 7(A) during which Employee is not permitted to
complete. The compensation provided in Subparagraph 7(B) shall
be reduced to the same extent as the noncompetition period is
reduced; provided that, this reduction in compensation shall not
reduce the compensation which may be owed to Employee pursuant
to Paragraph 3 or 8 of this Agreement.
8. Termination.
A. Notwithstanding the provisions of Paragraph 1, if the
Company terminates Employee's employment on or before August 31,
1995 or any August 31st thereafter for other than cause,
Employee shall, in addition to amounts otherwise due and owing
under this Agreement and in lieu of any other severance pay to
which Employee would otherwise be entitled, be entitled to
termination pay which shall equal 12 months base salary
beginning with the next September 1 following such termination.
Such base salary shall be at the rate provided in Exhibit A.
B. If the Company terminates Employee "for cause," he shall be
entitled to no severance pay and shall be entitled to no bonus
payment that might otherwise be owed to him even if he worked
for the entire year.Employee shall be deemed to have been
terminated by the Company "for cause" if he is terminated
because of his acts or conduct which would make it unreasonable
to require the Company to retain Employee in its employment,
such as, but not limited to, embezzlement or misappropriation
of corporate funds, other acts of dishonesty, improper
disclosure of any information concerning any matter affecting
or relating to the Company or the business of the Company,
activities harmful to the reputation of the Company, refusal to
perform or neglect of the substantive duties properly assigned
to Employee, a violation of any contractual, statutory or common
law duty of loyalty to the Company or breach of any of the
provisions of this Agreement.
C. If Employee voluntarily terminates his employment with the
Company, Employee shall not be entitled to, and shall not
receive, the cash bonus, if any, referred to in Exhibit A if he
did not work for the entire fiscal year.
D. If Employee should die or become disabled and unable to
perform his duties on or before August 31, 1995, or any
applicable subsequent August 31, he shall receive a cash bonus
equal to the cash bonus he would have received had he worked
for the entire fiscal year multiplied times a fraction, the
numerator of which equals the number of months transpiring
between September 1, 1994, or any applicable subsequent
September 1, and the last day of the month during which the
death or disability occurred, and the denominator of which is
twelve.
E. In the event Employee's employment shall end with the
Company prior to the termination date provided herein, or in
the event Employee shall act in violation of the provisions
of Paragraphs 4, 5, 6 or 7 of this Agreement or otherwise
breach this Agreement, Employee shall be subject to any and all
of the penalties contained in, or legal and equitable remedies
available to the Company resulting from, this Agreement.
9. DEKALB Antitrust Compliance Policy and Business Conduct
Standards. Employee acknowledges that he has received a copy of both
the DEKALB Antitrust Compliance Policy and the DEKALB Business
Conduct Standards adopted by the Board of Directors of DEKALB at its
meeting on May 15, 1990. Employee shall, to the best of Employee's
belief and ability, adhere to the policies and principles contained
therein, and will require all appropriate employees reporting to
Employee to adhere to those policies and principles.
10. New Employment. Employee will not begin employment with another
employer without first notifying the Company. Prior to accepting any
new employment, Employee shall inform his new employer of the
existence of this Agreement and provide a copy to such new employer.
The Company reserves the right to request separate written assurances
satisfactory to the Company from the Employee and from such new
employer that Employee will not be required to use or disclose secret
or confidential Company information as part of his new employment.
11. Life Insurance. The Company shall have the right, at its own
expense and for its own benefit, to take out life insurance on
Employee in such amount or amounts as it shall see fit, and Employee
agrees to cooperate with the Company in obtaining such insurance.
12. Designation of Beneficiary. The Beneficiary Designation form
attached hereto as Exhibit B shall be deemed to be a part of this
Agreement. In the event of Employee's death when no beneficiary
designation is in effect, the Company shall make payment of any
amounts to which Employee was entitled following Employee's death to
Employee's personal representative, heirs, devisees or legatees.
13. Remedies; Survival of Employee's Covenants. Without limiting
the rights of the Company to pursue all other legal and equitable
rights available to it for any violation of the covenants of Employee
herein, it is agreed that: (a) the services to be rendered by
Employee under this Agreement are of a special, unique, unusual and
extraordinary character which give them a peculiar value, and the
loss of such services cannot be reasonably and adequately compensated
in damages in an action at law, and (b) remedies other than
injunctive relief cannot fully compensate the Company for violation
of Paragraphs 4, 5, 6 or 7 of this Agreement; accordingly, the
Company shall be entitled to injunctive relief to prevent violations
of such paragraphs or continuing violations thereof. All of
Employee's covenants in and obligations under Paragraphs 4, 5, 6 and
7 of this Agreement shall continue in effect notwithstanding any
termination of Employee's employment, whether by the Company or by
Employee, upon expiration or otherwise, and whether or not pursuant
to the terms of this Agreement.
14. Modification. If, in any action before any court or agency
legally empowered to enforce them, any term, restriction, covenant or
promise contained herein is found to be unreasonable, unlawful or
otherwise invalid and for that reason unenforceable, then such term,
restriction, covenant or promise shall be deemed modified to the
extent necessary to make it enforceable by such court or agency.
15. Successors and Assigns. This Agreement shall be binding upon
the Company, its successors and assigns and upon Employee, Employee's
heirs, executors and administrators. This Agreement may be assigned
by the Company as part of the sale of its entire business, or to a
subsidiary or affiliate of the Company, or transferred by operation
of law. Employee agrees that if he is transferred to a subsidiary or
affiliate, or from one subsidiary or affiliate to another, all terms
and conditions of this Agreement shall remain in force as if it
initially had been made with that subsidiary or affiliate.
16. Notices. Notices contemplated by this Agreement shall be in
writing and shall be deemed given when delivered in person or mailed
registered first class mail postage prepaid, to the Company at 3100
Sycamore Road, DeKalb, IL 60115 or to Employee at 1101 Iroquois,
Apt. 2223, Naperville, IL 60563.
17. Integration. This Agreement, including Exhibits A and B as they
may be amended from time to time, all confidentiality agreements
signed by Employee during his employment with the Company, and all
invention assignment agreements signed by Employee during his
employment with the Company, contain the entire agreement between the
parties hereto with respect to the transactions contemplated herein;
together they supersede all prior negotiations and other agreements,
both oral and written, between the parties and they cannot be
amended, supplemented or modified except by an instrument in writing
signed by all parties.
IN WITNESS WHEREOF, this Agreement is entered into effective as of
the date set forth above.
DEKALB Genetics Corporation
By: Richard T. Crowder
Richard T. Crowder
<TABLE>
EXHIBIT 11
DEKALB Genetics Corporation
STATEMENT RE COMPUTATION OF PER SHARE EARNINGS
years ended August 31, 1995, 1994 and 1993
<CAPTION>
(Dollars in thousands except per share amounts)
Primary Earnings Per Share:
1995 1994 1993
<S> <C> <C> <C>
1. Average shares outstanding.....................................................5,163,502 5,141,422 5,130,940
2. Net additional shares outstanding assuming dilutive stock options exercised
and proceeds used to purchase treasury stock at average market price........ 95,075 79,616 62,863
3. Average number of common and common equivalent shares outstanding..............5,258,577 5,221,038 5,193,803
4. Net earnings for primary earnings per share computation........................ $10,758 $10,564 $1,715
5. Primary earnings per share..................................................... $2.04 $2.02 $0.33
</TABLE>
<PAGE>
EXHIBIT 21
Subsidiaries of DEKALB Genetics Corporation
The following table sets forth principal subsidiaries of the registrant and
indicates as to each such subsidiary the state or other jurisdiction under the
laws of which it was organized and the percentage of voting securities thereof
owned by the registrant.
Percentage of
Jurisdiction Voting Securities
of Owned by the
Incorporation Registrant
DEKALB Swine Breeders, Inc. Delaware 100%
DEKALB Argentina S.A. Argentina 100%
DEKALB Canada Inc. Ontario 100%
DEKALB Italia S.p.A. Italy 100%
The foregoing list does not name certain subsidiaries of subsidiaries and
certain companies reported on the equity basis as in the aggregate they are
not considered significant.
No financial statements are filed for companies in which the registrant
recognizes equity in undistributed earnings because all such companies in the
aggregate are not considered significant.
<PAGE>
EXHIBIT 23A
CONSENT OF INDEPENDENT ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation of
our report dated October 6, 1995, included in this Form 10-K, into the DEKALB
Genetics Corporation's previously filed Registration Statements No. 33-24875,
No. 33-33305 and No. 33-39986 on Form S-8.
Arthur Andersen LLP
Chicago, Illinois
October 11, 1995
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in the Registration
Statements No. 33-24875, No. 33-33305 and No. 33-39986 on Form S-8
of our reports dated October 12, 1994 except for Note S, as to which
the date is October 6, 1995, accompanying the consolidated
financial statements of DEKALB Genetics Corporation as of August 31, 1994
and for the years ended August 31, 1994 and 1993 included in this annual
report on Form 10-K of DEKALB Genetics Corporation.
Coopers & Lybrand L.L.P.
Chicago, Illinois
October 11, 1995
